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ABSTRACT 
Background and aims. Lidocaine is a widely used local anaesthetic agent that also has 
anti-arrhythmic effects. It is classified as a type Ib anti-arrhythmic agent and is used to 
treat ventricular tachycardia or ventricular fibrillation. Lidocaine is eliminated mainly by 
metabolism, and less than 5% is excreted unchanged in urine. Lidocaine is a drug with a 
medium to high extraction ratio, and its bioavailability is about 30%. Based on in vitro 
studies, the earlier understanding was that CYP3A4 is the major cytochrome P450 (CYP) 
enzyme involved in the metabolism of lidocaine. When this work was initiated, there was 
little human data on the effect of inhibitors of CYP enzymes on the pharmacokinetics of 
lidocaine. Because lidocaine has a low therapeutic index, medications that significantly 
inhibit lidocaine clearance (CL) could increase the risk of toxicity. These studies 
investigated the effects of some clinically important CYP1A2 and CYP3A4 inhibitors on 
the pharmacokinetics of lidocaine administered by different routes. 
 
Methods. All of the studies were randomized, double-blind, placebo-controlled cross-over 
studies in two or three phases in healthy volunteers. Pretreatment with clinically relevant 
doses of CYP3A4 inhibitors erythromycin and itraconazole or CYP1A2 inhibitors 
fluvoxamine and ciprofloxacin was followed by a single dose of lidocaine. Blood samples 
were collected to determine the pharmacokinetic parameters of lidocaine and its main 
metabolites monoethylglycinexylidide (MEGX) and 3-hydroxylidocaine (3-OH-
lidocaine). 
 
Results. Itraconazole and erythromycin had virtually no effect on the pharmacokinetics of 
intravenous lidocaine, but erythromycin slightly prolonged the elimination half-life (t½) of 
lidocaine (Study I). When lidocaine was taken orally, both erythromycin and itraconazole 
increased the peak concentration (Cmax) and the area under the concentration-time curve 
(AUC) of lidocaine by 40-70% (Study II). Compared with placebo and itraconazole, 
erythromycin increased the Cmax and the AUC of MEGX by 40-70% when lidocaine was 
given intravenously or orally (Studies I and II). The pharmacokinetics of inhaled lidocaine 
was unaffected by concomitant administration of itraconazole (Study III). Fluvoxamine 
reduced the CL of intravenous lidocaine by 41% and prolonged the t½ of lidocaine by 
35%. The mean AUC of lidocaine increased 1.7-fold (Study IV). After oral administration 
of lidocaine, the mean AUC of lidocaine increased 3-fold and the Cmax 2.2-fold by 
fluvoxamine (Study V). During the pretreatment with fluvoxamine combined with 
erythromycin, the CL of intravenous lidocaine was 53% smaller than during placebo and 
21% smaller than during fluvoxamine alone. The t½ of lidocaine was significantly longer 
during the combination phase than during the placebo or fluvoxamine phase. The mean 
AUC of intravenous lidocaine increased 2.3-fold and the Cmax 1.4-fold (Study IV). After 
oral administration of lidocaine, the mean AUC of lidocaine increased 3.6-fold and the 
Cmax 2.5-fold by concomitant fluvoxamine and erythromycin. The t½ of oral lidocaine was 
significantly longer during the combination phase than during the placebo (Study V). 
When lidocaine was given intravenously, the combination of fluvoxamine and 
erythromycin prolonged the t½ of MEGX by 59% (Study IV). Compared with placebo, 
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ciprofloxacin increased the mean Cmax and AUC of intravenous lidocaine by 12% and 
26%, respectively. The mean plasma CL of lidocaine was reduced by 22% and its t½ 
prolonged by 7% (Study VI). 
 
Conclusions. These studies clarify the principal role of CYP1A2 and suggest only a 
modest role of CYP3A4 in the elimination of lidocaine in vivo. The inhibition of CYP1A2 
by fluvoxamine considerably reduces the elimination of lidocaine. Concomitant use of 
fluvoxamine and the CYP3A4 inhibitor erythromycin further increases lidocaine 
concentrations. The clinical implication of this work is that clinicians should be aware of 
the potentially increased toxicity of lidocaine when used together with inhibitors of 
CYP1A2 and particularly with the combination of drugs inhibiting both CYP1A2 and 
CYP3A4 enzymes. 
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INTRODUCTION 
Variability in drug response can be due to either pharmacokinetic or pharmacodynamic 
factors. The reasons for people differing in pharmacokinetics or pharmacodynamics are 
manifold, including genetic factors, diseases, age and concomitantly administered drugs. 
As far as pharmacokinetics is concerned, oxidation reactions are dominant in the 
metabolism of drugs, and the cytochrome P450 (CYP) enzymes have been recognized as 
chief contributors (Wilkinson 2005). The primary organ for the biotransformation of drugs 
is the liver. However, CYP enzymes can be detected in several other organs as well. For 
example, the wall of the small intestine plays a major role in the presystemic elimination 
of many drugs, and intestinal drug metabolism can greatly reduce the oral bioavailability 
of drugs. 
Modern anaesthetic techniques involve combinations of drugs to produce synergistic 
or additive interactions. Furthermore, many patients coming to operations take 
medications unrelated to surgery. In fact, a pharmacoepidemiological study showed that 
half of the adult general surgery patients take medicines unrelated to surgery (Kennedy et 
al. 2000). 
Lidocaine is a popular amide-type local anaesthetic that is also widely used 
intravenously for ventricular arrhythmias. Lidocaine is not solely a local anaesthetic and 
an anti-arrhythmic drug. Intravenous lidocaine also has analgesic, anti-inflammatory and 
anti-hyperalgesic properties (Marret et al. 2008). Recently, several potential indications 
for lidocaine have emerged (Wright et al. 2008). Lidocaine is eliminated mainly by 
metabolism and less than 5% is excreted unchanged in urine. Lidocaine is a drug with a 
medium to high extraction ratio, and therefore, its clearance (CL) is significantly 
dependent on liver blood flow (Tucker and Mather 1979). After oral ingestion, lidocaine 
has extensive first-pass metabolism, resulting in a bioavailability of about 30%. The 
principal metabolic pathway of lidocaine is oxidative N-deethylation to 
monoethylglycinexylidide (MEGX). In human liver microsomes, lidocaine is also 
metabolized via hydroxylation to 3-hydroxylidocaine (3-OH-lidocaine) (Imaoka et al. 
1990). Based on in vitro studies, the earlier understanding was that CYP3A4 is mainly 
responsible for the formation of MEGX, whereas CYP1A2 is responsible for the 
production of 3-OH-lidocaine (Bargetzi et al. 1989, Imaoka et al. 1990). 
CYP-related drug interactions are known to affect the pharmacokinetics of several 
drugs. Erythromycin and itraconazole are inhibitors of CYP3A4. Itraconazole, for 
instance, increases the area under the oral midazolam concentration-time curve over 600% 
and reduces the clearance of midazolam by 70% (Olkkola et al. 1996). Fluvoxamine and 
ciprofloxacin inhibit CYP1A2 (Fuhr et al. 1992, Rasmussen et al. 1995).  
When this work was initiated, little human data existed on the effect of inhibitors of 
CYP enzymes in general on the pharmacokinetics of lidocaine. Because lidocaine has a 
low therapeutic index, medications that significantly inhibit its clearance, thereby 
increasing lidocaine plasma concentrations, could increase the risk of toxicity. If inhibiting 
CYP3A4 affects lidocaine to the same extent with, e.g., itraconazole, as it affects 
midazolam, it can be predicted that during long-term infusion of lidocaine, the dose would 
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be reduced by 70-80% or otherwise the targeted therapeutic concentrations would be 
exceeded 3- to 5-fold resulting in serious toxic reactions.  
Previous studies have shown that cimetidine, a non-specific inhibitor of CYP enzymes, 
reduces the plasma clearance of lidocaine significantly (Feely et al. 1982). Propafenone, 
an inhibitor of CYP2D6, reduces the clearance of lidocaine negligibly (Ujhelyi et al. 
1993). The ß-adrenoreceptor antagonist propranolol reduces lidocaine clearance by 20-
40% (Ochs et al. 1980), the reduction in lidocaine metabolism being apparently mediated 
both by enzyme inhibition and by the reduction of liver blood flow (Bax et al. 1985). In 
vitro studies show that propranolol does not affect the formation of MEGX, but inhibits 
the 3-hydroxylation of lidocaine mediated by CYP1A2 (Imaoka et al. 1990, Suzuki et al. 
1993). 
The present studies investigated the effects of some clinically important CYP1A2 and 
CYP3A4 inhibitors on the pharmacokinetics of lidocaine in healthy volunteers. 
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REVIEW OF THE LITERATURE 
1 Pharmacokinetics 
Pharmacokinetics refers to the phases and time course of a drug and its metabolites in the 
body or, more accurately, what the body does to the drug. Pharmacokinetics is often 
divided into absorption and disposition. Absorption describes the movement of a drug 
from the site of administration to the circulatory system. The rate of absorption is 
indirectly described by the peak plasma drug concentration (Cmax) and the time at which it 
occurs (tmax). Disposition consists of distribution and elimination. Distribution involves the 
transfer of a drug between plasma and tissues. Distribution initially occurs into highly 
perfused tissues, followed by slower uptake into muscle and fat. Elimination involves the 
loss of a drug from the body. Disposition, this combined process of distribution and 
elimination, is generally described by the clearance and the terminal elimination half-life 
(t½). 
The major mechanism for elimination of drugs from the body is metabolism; only 
relatively few drugs are eliminated unchanged by the kidneys (Rowland and Tozer 1995). 
The liver is the major organ for drug biotransformation, but drug-metabolizing enzymes 
are also present at other sites, such as the gastrointestinal and respiratory tracts, kidney, 
lung, brain and skin (Krishna and Klotz 1994). As in the liver, orally administered drugs 
can be subject to significant metabolism in the intestinal wall before they reach the 
systemic circulation. This phenomenon is referred to as first-pass, or presystemic, 
metabolism, and it can considerably decrease the oral bioavailability of many drugs. 
Most pharmacologically active molecules are lipophilic, which facilitates their passing 
through biological membranes. Lipophilic compounds need to be biotransformed into 
more hydrophilic metabolites in order to be excreted into urine or bile. This 
biotransformation is catalysed in humans by several drug-metabolizing enzymes. Drug 
metabolism has been traditionally classified into functionalization (phase I) and 
conjugation (phase II) reactions. The functionalization reactions include dehydrogenation 
or hydrogenation, oxidation, hydrolysis, reduction and mono-oxygenation (Meyer 1996). 
Most phase I metabolism reactions are catalysed by CYP enzymes in the endoplasmic 
reticulum. The enzymes involved in phase II reactions transfer water-soluble chemicals, 
such as glutathione, glucuronide or sulphate, to other compounds. They are located in both 
the cytoplasm and the endoplasmic reticulum. Many drugs undergo both phase I and phase 
II metabolism sequentially, but some can be excreted after either phase I or phase II 
reactions or even while still unmetabolized. And further, despite the nomenclature, phase 
II metabolism can occur in some unchanged drugs, and phase I enzymes can also 
metabolize conjugated drugs (Josephy et al. 2005).  
The metabolites produced by phase I and II reactions are usually inactive or less active 
than the parent drug. However, some metabolites may have enhanced activity (prodrugs) 
or toxic effects. Thus, changes in the activity of a drug-metabolizing enzyme can have 
different consequences depending on the properties of the drug. A decrease in enzyme 
activity leads to increased plasma concentrations of the substrate drug, which usually 
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means exaggerated effects and toxicity, and vice versa, an increase in enzyme activity 
leads to decreased plasma concentrations of the substrate, which can result in therapeutic 
failure due to lack of effect. Alterations in enzyme activity are most relevant in the case of 
drugs with a narrow therapeutic window. 
2 Cytochrome P450 enzymes 
In phase I human drug metabolism, CYP enzymes play a major role. The CYP enzymes 
comprise a superfamily of haem-containing mono-oxygenases. In the presence of carbon 
monoxide, they have an absorption maximum at a wavelength of 450 nm and are therefore 
called P450 (Nebert and Russell 2002). Human CYP enzymes are located intracellularly in 
the endoplasmic reticulum (microsomes). The CYP superfamily has been divided on the 
basis of structural homology into families (enzymes with >40% amino acid sequence 
similarity), which are then further classified into subfamilies (enzymes within a family 
having >55% amino acid similarity). Individual CYP enzymes are named by a number for 
the family (e.g. CYP3A4), a letter for the subfamily (CYP3A4) and a number for the 
individual enzyme (CYP3A4). Currently, there are 18 different known CYP families and 
44 subfamilies in humans, covering 57 CYP genes and 58 pseudogenes (Lewis 2004, 
Nelson et al. 2004) (http://drnelson.utmem.edu/CytochromeP450.html). Enzymes in 
families 1-3 have been traditionally thought to function mostly in the metabolism of a 
wide variety of xenobiotics, while other families are involved mainly in physiological 
functions such as the biosynthesis of fatty acids, steroid hormones and bile acids 
(Venkatakrishnan et al. 2001, Nebert and Russell 2002). The metabolism of over 90% of 
all drugs is estimated to be mediated, at least partially, by CYPs (Pelkonen et al. 2008). 
The estimated proportions of the major drug-metabolizing CYP enzymes in the human 
liver are as follows; CYP3A4/5/7 35%, CYP2C9 17%, CYP2E1 14%, CYP1A2 12%, 
CYP2A6 8%, CYP2C8 6%, CYP2C19 3%, CYP2B6 3% and CYP2D6 2% (Rostami-
Hodjegan and Tucker 2007, Figure 1). However, notable interindividual differences exist 
in the hepatic proportion of the different CYP enzymes. Furthermore, the hepatic 
abundance of a CYP enzyme does not correlate with the importance of the enzyme in drug 
metabolism. A typical feature of drug-metabolizing CYP enzymes is also broad and 
overlapping substrate specificity. CYP enzymes can be inhibited and induced by various 
drugs and other xenobiotics (Pelkonen et al. 2008). Examples of substrates, inhibitors and 
inducers of individual CYP isoenzymes are presented in Table 1. 
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Table 1. Examples of substrates, inhibitors and inducers of some drug-metabolizing 
CYP enzymes. 
CYP1A2 CYP2C8 CYP2C9 CYP2C19 CYP2D6 CYP3A4 
Substrates 
Caffeine1 Amiodarone9 Celecoxib13 Citalopram16 Amitriptyline17 Alfentanil1 
Clozapine2 Cerivastatin9 Diclofenac13 Diazepam16 Codeine17 Alprazolam1 
Melatonin1 Ibuprofen9 Fluvastatin13 Lansoprazole16 Dextromethorphan17 Atorvastatin1 
Ropivacaine3 Paclitaxel9 Ibuprofen13 Omeprazole16 Fluoxetine17 Carbamazepine19 
Theophylline1 Pioglitazone10 Losartan13 Phenobarbital16 Fluvoxamine17 Cyclosporin1 
Tizanidine4 Repaglinide11 Naproxen13 Proguanil16 Haloperidol17 Dexamethasone19 
 Rosiglitazone9 Phenytoin13 Propranolol16 Metoprolol17 Diltiazem19 
  S-warfarin13  Oxycodone17 Erythromycin1 
    Paroxetine17 Felodipine1 
    Propafenone17 Lovastatin1 
    Rispridone17 Midazolam1 
    Tramadol18 Nifedipine1 
     Simvastatin1 
     Tacrolimus1 
     Triazolam1 
     Verapamil19 
Inhibitors 
Ciprofloxacin5 Gemfibrozil9 Amiodarone14 Fluconazole1 Fluoxetine1 Clarithromycin19 
Fluvoxamine6 Trimethoprim9 Fluconazole14 Fluvoxamine16 Paroxetine1 Diltiazem19 
Furafylline1  Miconazole14 Ketaconazole16 Quinidine1 Erythromycin19 
Rofecoxib7  Sulfaphenazole14 Omeprazole16 Terbinafine1 Grapefruit juice1 
  Voriconazole15   HIV protease 
inhibitors19 
     Itraconazole1 
     Ketoconazole1 
     Voriconazole15 
Inducers 
Cigarette 
smoke1 
Phenobarbital12 Phenobarbital12 Phenobarbital12 Not known Carbamazepine1 
Omeprazole8 Rifampicin12 Rifampicin12 Rifampicin12  Dexamethasone1 
     Phenobarbital1 
     Phenytoin1 
     Rifampicin1 
Rererences: 1Pelkonen et al. (2008), 2Bertilsson et al. (1994), 3Jokinen et al. (2000), 4Granfors et al. (2004), 
5Fuhr et al. (1992), 6Rasmussen et al. (1995), 7Backman et al. (2006), 8Gunes and Dahl (2008), 9Totah and 
Rettie (2005), 10Jaakkola et al. (2006a), 11Kajosaari et al. (2005), 12Gerbal-Chaloin et al. (2001), 13Rettie and 
Jones (2005), 14Miners and Birkett (1998), 15Theuretzbacher et al. (2006), 16Desta et al. (2002), 17Zanger et 
al. (2004), 18Stamer and Stuber (2007), 19Dresser et al. (2000). 
 
 
 
 
15
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Relative abundances of CYP enzymes in the human liver. 
2.1 CYP1 family 
The CYP1A subfamily consists of two members: CYP1A1 and CYP1A2. CYP1A1 is 
expressed mainly in extrahepatic tissues such as the lung, skin, larynx and placenta, 
whereas CYP1A2 is expressed mainly in the liver (Gunes and Dahl 2008). The substrate 
specificity of CYP1A1 overlaps with that of CYP1A2, but it is of little importance in drug 
metabolism due to localization. 
CYP1A2 is important in the metabolism of several drugs, including caffeine, 
clozapine, ropivacaine, theophylline and tizanidine (Bertilsson et al. 1994, Jokinen et al. 
2000, Granfors et al. 2004, Pelkonen et al. 2008). CYP1A2 is also involved in the 
biotransformation of some endogenous compounds, e.g. melatonin, and in the elimination 
of environmental toxins as well as the bioactivation of environmental procarcinogens 
(Härtter et al. 2001, Faber et al. 2005). Fluvoxamine, ciprofloxacin and rofecoxib are 
known inhibitors of CYP1A2 (Fuhr et al. 1992, Rasmussen et al. 1995, Backman et al. 
2006). CYP1A2 can be induced by environmental factors, such as polycyclic aromatic 
hydrocarbons found in, for example, cigarette smoke and chargrilled food. Other inducers 
include dietary agents in, for instance, cruciferous vegetables, and drugs such as 
omepratzole (Gunes and Dahl 2008). Large interindividual and intraindividual variability 
of CYP1A2 activity has been found in humans (Faber et al. 2005). CYP1A2 expression 
varies up to 40-fold, and there is a corresponding variability of enzyme activity and drug 
metabolism (Gunes and Dahl 2008). Although the CYP1A2 gene shows structural 
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polymorphism (http://www.cypalleles.ki.se/cyp1a2.htm), its importance in explaining 
variability in CYP1A2 activity is unclear. 
2.2 CYP2 family 
CYP2A6 is a predominantly hepatic enzyme. Its most specific substrates include 
coumarin and nicotine. CYP2A6 is inhibited by methoxsalen and induced by 
phenobarbital (Pelkonen et al. 2008). CYP2A6 is highly polymorphic, and its genotype 
has been associated with, for example, smoking behaviour (Ingelman-Sundberg et al. 
2007). 
CYP2B6 has recently been recognized to be a clinically important enzyme in drug 
metabolism. It is mainly a hepatic enzyme, but is also expressed at lower levels in several 
extrahepatic tissues, including the brain, lung, nasal mucosa and trachea. It is highly 
polymorphic (Walsky et al. 2006). CYP2B6 metabolizes bupropion, methadone and 
propofol (Oda et al. 2001, Walsky et al. 2006, Totah et al. 2008). Clopidogrel and 
ticlopidine are potent inhibitors of CYP2B6 (Turpeinen et al. 2005). It is inducible by 
rifampicin (Pelkonen et al. 2008). 
The importance of CYP2C8 in drug metabolism, like that of CYP2B6, has been 
clarified recently (Ingelman-Sundberg et al. 2007). CYP2C8 is expressed mainly in the 
liver, where it has a major role in the metabolism of many drugs, including amiodarone, 
cerivastatin, paclitaxel, repaglinide and rosiglitazone (Rahman et al. 1994, Baldwin et al. 
1999, Ohyama et al. 2000, Wang et al. 2002b, Bidstrup et al. 2003). Furthermore, certain 
endogenous agents, such as arachidonic acid, can be metabolized by CYP2C8 (Rifkind et 
al. 1995). CYP2C8 inhibitors include gemfibrozil and trimethoprim (Wang et al. 2002b, 
Wen et al. 2002). Montelukast is a selective and potent inhibitor of CYP2C8 in vitro, but 
due to its low free concentration in plasma, it does not inhibit CYP2C8 in vivo (Jaakkola 
et al. 2006b). CYP2C8 is induced by rifampicin (Gerbal-Chaloin et al. 2001). Several 
functional CYP2C8 polymorphisms have been published (Dai et al. 2001, Niemi et al. 
2003, Martinez et al. 2005, Rodriguez-Antona et al. 2008). 
CYP2C9 is the most abundant CYP2C isoform in both the liver and intestine (Läpple 
et al. 2003). Its substrates include many clinically important drugs, e.g. S-warfarin, 
losartan, phenytoin and many non-steroidal anti-inflammatory drugs (NSAIDs) (Rettie 
and Jones 2005). Amiodarone, sulphafenazole and several azole antifungals inhibit 
CYP2C9, and it is induced by rifampicin and barbiturates (Miners and Birkett 1998, 
Pelkonen et al. 2008). CYP2C9 polymorphisms have functional consequences for 
pharmacokinetics as well as for clinical drug response and side-effects (Kirchheiner and 
Brockmöller 2005). 
CYP2C19 participates in the metabolism of many commonly used drugs, e.g. 
citalopram, diazepam, omeprazole, phenobarbital, proguanil and propranolol (Desta et al. 
2002). No selective inhibitors for CYP2C19 have been found, but at least omeprazole and 
fluconazole inhibit this enzyme (Funck-Brentano et al. 1997, Kang et al. 2002). The 
inducers of CYP2C19 include rifampicin and artemisinin (Desta et al. 2002). CYP2C19 is 
also polymorphically expressed. Only 2-5% of Caucasians, but up to 20% of Orientals are 
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poor metabolizers of CYP2C19 (Ingelman-Sundberg et al. 2007). CYP2C19 genotype has 
been shown to influence the efficacy of proton pump inhibitor treatment (Klotz et al. 
2004). 
CYP2D6 plays a central role in drug metabolism in humans. It is responsible for the 
clearance of 25% of the compounds in current clinical use, and its polymorphisms can 
affect the metabolism of 50% of these drugs (Ingelman-Sundberg et al. 2007). In addition 
to the liver, CYP2D6 is expressed at lower levels in the gastrointestinal tract and brain. Its 
substrates comprise many anti-arrhythmics, anti-emetics, antipsychotics, selective 
serotonin reuptake inhibitors (SSRI), tricyclic antidepressants, beta-blockers and opioids, 
e.g. dextromethorphan (Zanger et al. 2004). Furthermore, CYP2D6 is important in the 
bioactivation of the prodrugs codeine and tramadol (Stamer and Stuber 2007). This 
isoenzyme is inhibited by many drugs, including quinidine and terbinafine (Pelkonen et al. 
2008). CYP2D6 is the only CYP enzyme involved in drug metabolism that is not 
inducible (Ingelman-Sundberg et al. 2007). CYP2D6 exhibits significant polymorphism, 
ranging from null alleles to multiple copies of active alleles. Individuals can be divided 
into poor, intermediate, extensive and ultrarapid metabolizers according to the activity of 
CYP2D6 (Zanger et al. 2004). 
CYP2E1 has mainly toxicological relevance since it is involved in the formation of 
many carcinogens and reactive metabolites, such as the hepatotoxic metabolite of 
paracetamol. This isoenzyme participates in the metabolism of chlorzoxazone, ethanol, 
paracetamol and many halogenated anaesthetics, including enflurane, halothane, 
isoflurane and sevoflurane (Tanaka et al. 2000). Inhibitors of CYP2E1 include disulfiram 
and pyridine, and it is induced by ethanol and isoniazid (Pelkonen et al. 2008). 
2.3 CYP3 family 
CYP3A enzymes are the most important oxidative enzymes in drug metabolism. They 
account for approximately 40% of the total CYP content in the human liver and have been 
estimated to participate in the metabolism of >50% of all marketed drugs (Liu et al. 2007). 
The CYP3A subfamily of enzymes consists of four isoforms; CYP3A4, CYP3A5, 
CYP3A7 and CYP3A43. 
CYP3A4 is mainly located in the liver, but it is also the most abundant CYP enzyme 
in the intestine (Kivistö et al. 1996). In addition, it is expressed in the lung, kidney, brain 
and prostate (Anttila et al. 1997, Zhou 2008b). The active site of CYP3A4 is large and 
flexible so that many preferentially lipophilic compounds can bind to it. Its substrates 
include the opioid alfentanil, the benzodiazepines midazolam and triazolam, several 
calcium-channel blockers, the HMG-CoA reductase inhibitors atorvastatin and 
simvastatin, the immunosuppressants cyclosporine and tacrolimus, macrolide antibiotics 
such as erythromycin, and many others. Relatively low substrate specificity makes 
CYP3A4 susceptible to inhibition by a broad variety of structurally unrelated substances. 
On the other hand, drug interactions caused by inhibition of CYP3A4 exhibit substantial 
substrate dependency (Pelkonen et al. 2008). Its inhibitors include the azole antifungals 
ketoconazole and itraconazole, the calcium-channel blockers diltiazem and verapamil, the 
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macrolide antibiotics clarithromycin, erythromycin and troleandomycin, the human 
immunodeficiency virus (HIV) protease inhibitors and grapefruit juice (Dresser et al. 
2000, Pelkonen et al. 2008). Both hepatic and intestinal CYP3A4 can be induced by 
several drugs such as carbamazepine, dexamethasone, phenobarbital, phenytoin and 
rifampicin (Luo et al. 2004). There is a high degree of interindividual variability in 
CYP3A4 activity. Numerous variants of CYP3A4 alleles have been found, but their 
frequencies are very low, and they are unlikely to explain the variability in CYP3A4 
activity (Zanger et al. 2008). 
CYP3A5 is found mainly in the liver, but it is also expressed in the intestine. 
Furthermore, it is the dominant CYP3A form in the kidney and lung (Kivistö et al. 1996, 
Lamba et al. 2002). The substrate specificity of CYP3A5 is similar, but not identical, to 
that of CYP3A4. However, the catalytic efficiency of CYP3A5 is usually weaker, and it 
can be less susceptible to inhibition than CYP3A4. CYP3A5 is genetically polymorphic, 
and it is significantly expressed in livers of only about 20% of Caucasians. However, in 
some individuals CYP3A5 can represent up to 50% of total hepatic CYP3A content (Daly 
2006). CYP3A5 polymorphism seems to explain the interindividual variability of some 
CYP3A substrates such as tacrolimus (Zanger et al. 2008). 
CYP3A7 is predominantly expressed in the fetal liver, but some adults continue to 
express this isoenzyme. CYP3A43 is expressed in relatively high levels in the prostate and 
testes, but its expression in the liver is low, and its function remains unknown (Daly 
2006). 
2.4 Inhibition and induction of CYP enzymes 
CYP enzymes play a central role in the metabolism of drugs, and inhibition or induction 
of these enzymes can alter the plasma concentrations and effects of their substrate drugs. 
Inhibition of CYP enzymes has been considered to be the most common cause of harmful 
drug-drug interactions (Pelkonen et al. 2008). Inhibition of a drug-metabolizing enzyme 
can lead to decreased clearance and increased plasma concentrations of its substrate 
compound, thus increasing the likelihood of adverse effects and toxicity. By contrast, in 
the case of prodrugs, inhibition can reduce the clinical efficacy of the substrate drug. CYP 
enzyme inhibition usually occurs rapidly, even after a single dose of the inhibitor (Lin and 
Lu 1998). 
Mechanisms of inhibition 
The mechanisms of enzyme inhibition can be divided roughly into three categories: 
reversible, quasi-irreversible and irreversible (Lin and Lu 1998). 
Reversible inhibition can be further divided, based on enzyme kinetics, into 
competitive, non-competitive, uncompetitive and mixed-type inhibition. In competitive 
inhibition, the inhibitor competes with the substrate for the same binding site within a 
CYP enzyme. Competitive inhibitors are often but not necessarily substrates for the 
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enzyme they inhibit. Typical competitive inhibitors of CYP enzymes include the CYP3A4 
inhibitor itraconazole and the CYP1A2 inhibitor ciprofloxacin (Pelkonen et al. 2008). In 
non-competitive inhibition, the active binding sites of the substrate and inhibitor differ 
from each other, but are located in the same enzyme. In uncompetitive inhibition, the 
inhibitor binds to the enzyme-substrate complex and makes the complex catalytically 
inactive. In practice, reversible inhibition often displays elements of both competitive and 
non-competitive inhibition, and thus, is called mixed-type inhibition (Lin and Lu 1998). 
Irreversible inhibition requires metabolic activation by the enzyme and is therefore 
known as mechanism-based inactivation (Obach et al. 2007). In irreversible inhibition, an 
inhibitor is metabolically activated by the CYP enzyme, and this inhibitory metabolite 
then forms a stable metabolic intermediate (MI) complex with the prosthetic haem of 
CYP, rendering the enzyme functionally inactive. The difference between quasi-
irreversible and irreversible inhibition is that in the former this MI complexation can be 
reversed in vitro. Irreversible inhibition is often long-lasting because it is reversed only by 
a synthesis of new, catalytically active enzymes. Erythromycin is an example of a quasi-
irreversible inhibitor of CYP3A (Lin and Lu 1998). Typical mechanism-based inhibitors 
include the CYP1A2 inhibitor furafylline and the CYP3A4 inhibitor gestodene (Pelkonen 
et al. 2008). 
 
Induction of CYP enzymes 
Induction is an adaptive process in which long-term exposure to drugs or environmental 
agents produces an upregulation in the amount of drug-metabolizing enzymes. Thus, 
induction leads to decreased plasma concentrations and often reduced pharmacological 
activity of the substrate drug. Drugs or environmental agents can induce CYP enzymes by 
enhancing the rate of their synthesis or by reducing their rate of degradation. Increased 
synthesis of CYPs is mediated by a group of ligand-activated transcription factors, which 
include intracellular aryl hydrocarbon receptor (AhR) and nuclear receptors, pregnane X 
receptor (PXR) and constitutive androstane receptor (CAR). The inducer binds to and 
activates one or more of these receptors, leading to increased transcription of the 
respective CYP enzymes. Contrary to CYP inhibition, induction is a slow process and can 
usually be seen only days or even weeks after exposure to the inducer has begun, and it 
may require multiple dosing with the inducing compound (Lin 2006). Common inducers 
of CYP enzymes comprise antiepileptic drugs, polycyclic aromatic hydrocarbons and 
rifampicin (Pelkonen et al. 2008). 
3 Drug transporters 
Transporters are increasingly recognized to be essential in drug absorption, distribution 
and excretion. Therefore, both metabolism by CYP enzymes and transport mechanisms 
should be considered when predicting in vivo pharmacokinetics of a drug. In addition to 
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drugs, transporters have important roles in transporting endogenous substances such as 
amino acids, bile acids, glucose, lipids, steroids and hormones (Ho and Kim 2005). Based 
on the direction of movement, transporters are usually divided into efflux and uptake 
transporters. The inhibition and induction of drug transporters follow the same principles 
as seen with drug-metabolizing enzymes. In addition to drug-induced changes in 
transporter activity, many transporters also exhibit genetic polymorphism (Ho and Kim 
2005, Maeda and Sugiyama 2008). 
Efflux transporters transport compounds out of the cell. They act to limit the entry of 
drugs or to assist their removal from the cell. The best-known efflux transporter is P-
glycoprotein (MDR1, multidrug resistance protein 1), a member of the ATP-binding 
cassette transporter protein family. It is a transmembrane protein that mediates the 
transport of various compounds through cell membranes. High levels of P-glycoprotein 
have been identified on the luminal surfaces of the small and large intestine, in proximal 
tubules of the kidneys and on the luminal surface of the biliary tract and hepatocytes. P-
glycoprotein is involved in the excretion of substances into urine, intestinal lumen and bile 
(i.e. reduced absorption) and has an important role in the blood-brain barrier (Fromm 
2004). There is overlapping substrate specificity between P-glycoprotein and CYP3A4, 
and there are also similarities in the inhibitors and inducers of CYP3A4 and P-
glycoprotein (Zhang and Benet 2001). Substrate drugs for P-glycoprotein include 
anticancer drugs, digoxin and HIV protease inhibitors. Itraconazole, erythromycin, 
verapamil and cyclosporine are inhibitors of P-glycoprotein. An inducer of P-glycoprotein 
is rifampicin (Zhou 2008a). Other efflux transporters include the multidrug resistance-
associated protein (MRP) family and the breast cancer resistance protein (BRCP) (Ho and 
Kim 2005). 
Uptake transporters enhance the entry of drugs into cells. This category of transporters 
includes the organic anion transporting polypeptide (OATP), organic anion transporter 
(OAT), organic cation transporter (OCT), organic cation/carnitine transporter (OCTN) and 
peptide transporter (PEPT) families. The OATPs are expressed in the intestine, liver, 
kidney and brain (Ho and Kim 2005). These transporters have several clinically important 
substrates such as bile salts, steroid conjugates, thyroid hormones, digoxin, HMG-CoA 
reductase inhibitors (statins) and methotrexate. OATPs can be inhibited by cyclosporine, 
rifampicin, gemfibrozil and macrolides, e.g. erythromycin (Niemi 2007). 
4 Lidocaine 
Lidocaine is an amide-type local anaesthetic agent with an intermediate duration of action. 
Lidocaine is also a class Ib anti-arrhythmic agent that can be used intravenously in the 
acute treatment and prevention of ventricular arrhythmias, especially after myocardial 
infarction. Lidocaine was synthesized in 1943, being the first amino amide-type local 
anaesthetic compound used in clinical practice (Covino 1986). 
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Figure 2 Chemical structures of lidocaine, MEGX and 3-OH-lidocaine. 
4.1 Pharmacology 
Structurally, lidocaine is an amide derivative of diethylamino acetic acid, and, like other 
amide-type local anaesthetics, it consists of a lipophilic aromatic ring attached by an 
amide linkage to a hydrophilic amino group. Lidocaine has a molecular weight of 234 
(base). Lidocaine is a weak base with a pKa of 7.9. Thus, at a physiological pH of 7.4, 
about 65% of lidocaine is in the charged cationic form and 35% in the uncharged base 
form. Because the uncharged form is primarily responsible for diffusion across the nerve 
sheath and membrane, the onset of action of lidocaine is fast compared with other local 
anaesthetics (Covino 1986). 
Lidocaine slows down the depolarization of the nerve cell membrane by reversibly 
blocking the fast voltage-gated sodium channels in the cell membrane. The membrane 
fails to transmit an action potential, which leads to an anaesthetic effect. In the heart, 
lidocaine reduces the automaticity in the conductive system by slowing down the diastolic 
depolarization. Lidocaine inhibits transmembrane sodium influx into the His-Purkinje 
fibre conduction system, thereby decreasing conduction velocity. It also decreases the 
duration of the action potential, and as a result, decreases the duration of the absolute 
refractory period in Purkinje fibres and bundle of His. Lidocaine also raises the ventricular 
fibrillation threshold and increases the electrical stimulation threshold of the ventricle 
during diastole. Atrioventricular nodal conduction time is unchanged or shortened by 
lidocaine (Sweetman 2009). 
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At therapeutic plasma concentrations, 64-70% of lidocaine is bound to plasma proteins 
(Benowitz and Meister 1978, Tucker and Mather 1979). Less is bound at higher plasma 
concentrations, e.g. at concentrations of 6-10 µg/ml, only 60%. Lidocaine is mainly bound 
to the acute phase reactant α1-acid glycoprotein (AAG). Plasma concentrations of AAG 
are increased as a result of various pathophysiological conditions, such as surgery, trauma 
and certain disease states, with a subsequent rise in plasma protein binding. Thus, the free 
fraction of lidocaine may vary up to eightfold, being relatively low in, for instance, 
postoperative and post-myocardial infarction patients (Tucker 1986). 
4.2 Pharmacokinetics 
Absorption 
Lidocaine is readily absorbed from mucous membranes and through damaged skin. 
Absorption through intact skin is poor (Sweetman 2009). Lidocaine is rapidly absorbed 
from the upper airway, tracheobronchial tree and alveoli into the bloodstream (DiFazio 
1981). It is also well-absorbed from the gastrointestinal tract, but oral bioavailability is 
only 35% due to extensive first-pass metabolism (Boyes et al. 1971). When injected into 
tissues, lidocaine is rapidly absorbed. The absorption rate is related to vascularity and the 
presence of tissue and fat capable of binding lidocaine of the particular tissues. Thus, the 
absorption rate from the site of injection decreases in the order intercostal > paracervical > 
lumbal epidural > brachial > spinal > subcutaneous (Tucker and Mather 1979, Tozer and 
Rowland 2006). The peak plasma concentrations following administration of lidocaine by 
various routes are presented in Appendix 1. Addition of a vasoconstrictor, e.g. 
epinephrine, to the solution reduces the rate of absorption by limiting the local blood flow, 
and therefore, the local anaesthetic effect is prolonged. 
 
Distribution 
When lidocaine is administered intravenously, it is rapidly distributed into highly perfused 
tissues, which achieve fast equilibration, followed by redistribution into skeletal muscle 
and adipose tissue, which reach equilibration slower. Thus, lidocaine plasma 
concentrations decline rapidly after an intravenous dose, with an initial half-life of less 
than 30 min. The elimination half-life (t½) is 1-2 h. The t½ may be prolonged if lidocaine is 
administered with an infusion lasting longer than 24 h, or if hepatic blood flow is reduced. 
Lidocaine has a steady-state volume of distribution (Vss) in the range of 50-160 litres 
(Benowitz and Meister 1978).  
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Elimination 
Lidocaine is eliminated mainly metabolically, with less than 5% of the dose excreted 
unchanged in urine (Tucker and Mather 1979). Like the volume of distribution, the 
clearance of lidocaine varies markedly in healthy volunteers; estimates for plasma 
clearance range from 0.54 to 1.44 l/min. Lidocaine is a drug with a medium to high 
extraction ratio (0.65), and therefore, its clearance is significantly dependent on liver 
blood flow (Benowitz and Meister 1978). Consequently, an inverse relationship exists 
between lidocaine levels and estimated hepatic blood flow (Stenson et al. 1971). 
The metabolism of lidocaine has been thoroughly investigated since the drug entered 
the market more than half a century ago. However, the metabolism has been shown to be 
complex, and different results have been obtained from in vitro and in vivo studies. The 
principal metabolic pathway of lidocaine is oxidative N-deethylation to MEGX, which is 
further de-ethylated to 2,6-xylidine and glycinexylidide (GX). 2,6-xylidine is hydrolysed 
to 4-hydroxy-xylidine, which is the major metabolite found in urine (Keenaghan and 
Boyes 1972, Tucker and Mather 1979). Based on in vitro studies, this hydroxylation is 
catalysed by CYP2A6 (Gan et al. 2001). Although 4-hydroxy-xylidine appears to be 
formed mainly from MEGX, evidence has emerged that some 4-hydroxy-xylidine is 
formed via direct hydrolysis of lidocaine (Nelson et al. 1974). A minor metabolic pathway 
of lidocaine is hydroxylation of the aromatic ring to form 3-OH-lidocaine (Hermansson et 
al. 1980). All hydroxylated metabolites are prone to subsequent phase II conjugation 
reactions (Falany et al. 1999). 
Earlier in vitro studies with human liver microsomes suggested that the formation of 
MEGX and 3-OH-lidocaine is catalysed mainly by CYP3A4 and CYP1A2, respectively 
(Bargetzi et al. 1989, Imaoka et al. 1990). Therefore, lidocaine was initially considered to 
be a probe for in vivo assessment of CYP3A4 activity (Brockmöller and Roots 1994). In a 
recent review article, lidocaine is still presented as a model substrate of CYP3A4 (Zhou 
2008b). Accordingly, the MEGX test, which measures the formation of MEGX following 
an intravenous bolus of lidocaine, has been used as a marker to evaluate the in vivo 
activity of hepatic CYP3A4 and as a dynamic test of liver function (Reichel et al. 1998, 
Sakka 2007). However, recent in vitro studies by Wang et al. (1999a, 2000) confirm that 
both CYP3A4 and CYP1A2 are important in the metabolism of lidocaine, but their 
relative roles can differ at different lidocaine concentrations. There is also some evidence 
that CYP2C9 can catalyse the formation of MEGX, but its role seems to be negligible 
(Wang et al. 2000, Nagashima et al. 2005). CYP1A2 appears to be the major enzyme 
catalysing the formation of both MEGX and 3-OH-lidocaine at therapeutically relevant 
plasma lidocaine concentrations. 
Some evidence has emerged of extrahepatic formation of MEGX. After lidocaine 
injection, formation of MEGX was demonstrated in a patient in unhepatic phase waiting 
for a liver transplant (Sallie et al. 1992). 
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P-glycoprotein 
P-glycoprotein seems to have a negligible role in the transport of lidocaine. In both in situ 
and in vitro absorption models, the jejunal permeability of lidocaine was high, but carrier-
mediated intestinal efflux apparently did not have a significant role (Berggren et al. 2004). 
In rats, the P-glycoprotein inhibitor quinidine failed to reduce the plasma concentration 
threshold for lidocaine-induced convulsions (Funao et al. 2003). However, based on a 
structure-activity relationship analysis, lidocaine could exhibit some P-glycoprotein 
inhibitory activity (Wang et al. 2003). 
4.3 Drug interactions 
At the time that this study commenced, little human data were available on the effect of 
CYP enzymes in general on the pharmacokinetics of lidocaine. Specifically, there was 
virtually no data on the effect of effective CYP1A2 or CYP3A4 inhibitors on the 
pharmacokinetics of lidocaine.  
The histamine-2 receptor antagonist cimetidine reduced the plasma clearance and Vss 
of intravenous lidocaine by 20-25% and 7-21%, respectively, and increased lidocaine Cmax 
by 50%, resulting in lidocaine toxicity (Feely et al. 1982, Wing et al. 1984). Cimetidine 
increased the oral bioavailability of lidocaine by 35% (Wing et al. 1984). When lidocaine 
was applied to the oropharynx, the area under the concentration-time curve (AUC) of 
lidocaine was increased by approximately 50% by concomitant cimetidine (Parish et al. 
1987). Ranitidine, another histamine-2 receptor antagonist, had only little or no effect on 
the metabolism of either oral or intravenous lidocaine (Jackson et al. 1985, Robson et al. 
1985). Both cimetidine and ranitidine are non-specific inhibitors of CYP enzymes, but 
cimetidine appears to be stronger (Bertz and Granneman 1997). In addition to enzyme 
inhibition, cimetidine reduces liver blood flow up to about 30% (Feely et al. 1981). 
Omeprazole, an inhibitor of the CYP2C19 isoenzyme, had no effect on the disposition of 
intravenous lidocaine (Noble et al. 1994), and the anti-arrhythmic agent propafenone, an 
inhibitor of the CYP2D6 isoenzyme, reduced the clearance of lidocaine negligibly 
(Ujhelyi et al. 1993). 
Some earlier studies have investigated the effect of ß-adrenoreceptor antagonists on the 
pharmacokinetics of lidocaine. Although the mechanism of this interaction has been 
somewhat controversial, the reduction in lidocaine metabolism seems to be mediated by 
both enzyme inhibition and reduction of liver blood flow (Tucker et al. 1984). ß-
adrenoreceptor antagonists have a variable effect on lidocaine metabolism in vitro, and 
they can either decrease or have no effect on hepatic blood flow. Atenolol is a ß-
adrenoreceptor antagonist that has little impact on lidocaine metabolism in vitro and does 
not change hepatic blood flow (Tucker et al. 1984). It also does not affect the 
pharmacokinetics of either oral or intravenous lidocaine in humans (Miners et al. 1984). 
Propranolol reduces both the intrinsic clearance of lidocaine and the hepatic blood flow. 
Thus, it is understandable that propranolol increased the AUC of oral lidocaine by over 
100% (Bax et al. 1985) and reduced the clearance of intravenous lidocaine by 40% (Ochs 
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et al. 1980). In addition, propranolol prolonged the t½ of lidocaine by over 50% and 
increased the steady-state plasma concentrations of lidocaine during a 35- to 36-h infusion 
by 30% (Ochs et al. 1980).  However, in a rat model, propranolol increased the threshold 
for lidocaine-induced convulsions apparently by acting directly on the brain (Nakamura et 
al. 2008). 
Unfortunately, there is little information available on the effects of the ß-
adrenoreceptor antagonists on individual CYP isoenzymes. In vitro, propranolol is a 
potent CYP2D6 inhibitor and a moderate CYP1A2 inhibitor (Turpeinen et al. 2006). 
Studies in rat liver microsomes have shown that propranolol competitively inhibits the 3-
hydroxylation of lidocaine, but does not affect the formation of MEGX from lidocaine 
(Suzuki et al. 1993). Propranolol can also decrease the binding of lidocaine in liver tissues 
(Tesseromatis et al. 2007). In human liver microsomes, propranolol inhibits both the 
hydroxylation and deethylation of lidocaine (Al-Asady et al. 1989).  
There are isolated reports of a pharmacokinetic and pharmacodynamic interaction 
between lidocaine and amiodarone, another anti-arrhythmic drug (Keidar et al. 1982, 
Siegmund et al. 1993). In six patients, amiodarone increased the AUC of lidocaine by 
about 20% and decreased the clearance of lidocaine by about 20% (Ha et al. 1996). This 
interaction was explained by the inhibition of CYP3A4 by amiodarone and/or its main 
metabolite desethylamiodarone.  
Addition of the α2-specific adrenergic agonist clonidine to lidocaine increases the 
duration of anaesthesia. This effect may be explained by both pharmacodynamic and 
pharmacokinetic interactions (Kopacz and Bernards 2001, Pratap et al. 2007). However, in 
an in vitro study, microsomal lidocaine de-ethylation was not altered by clonidine 
(Inomata et al. 2003a). 
Mexiletine is an anti-arrhythmic drug with structural similarity to lidocaine. It may 
increase the toxicity of lidocaine (Geraets et al. 1992, Christie et al. 1993). In a study of 
rabbits, the concurrent use of mexiletine and lidocaine resulted in a decrease in the 
clearance of lidocaine and an increase in lidocaine plasma levels. This interaction was 
interpreted to be due to mexiletine displacing the tissue binding of lidocaine and reducing 
its distribution (Maeda et al. 2002). 
Midazolam is a short-acting hypnotic and anxiolytic agent, which is metabolized 
substantially by CYP3A4 (Pelkonen et al. 2008). In human liver microsomes, lidocaine 
metabolism was non-competititively inhibited by midazolam (Nagashima et al. 2005). 
Propofol, an intravenous anaesthetic agent, inhibits CYP3A4 and decreases the 
clearance of, for instance, midazolam (Hamaoka et al. 1999). In vitro, propofol has a dose-
dependent inhibitory effect on the formation of MEGX from lidocaine (Inomata et al. 
2003b). However, in patients, propofol infusion did not alter the metabolism of epidural 
lidocaine compared with sevoflurane (Nakayama et al. 2004). Accordingly, a bolus dose 
of propofol had no effect on serum lidocaine concentrations in smokers and chronic 
alcohol users (Elmas et al. 2003). 
Argatroban, a direct thrombin inhibitor, is metabolized by CYP3A4/5. In healthy 
volunteers, no pharmacokinetic interactions were detected between argatroban and 
lidocaine (Inglis et al. 2002). 
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While this study was in progress, two other studies on the interactions of CYP3A4 
inhibitor erythromycin and lidocaine were published. Swart et al. (2002) reported that 
erythromycin 500 mg four times daily for five days had no significant effect on the 
disposition kinetics of intravenous lidocaine. By contrast, Orlando et al. (2003) reported 
that a pretreatment with four doses of erythromycin 600 mg decreased the clearance of 
intravenous lidocaine by about 20%, prolonged the t½ of lidocaine by 30%, and increased 
the AUC of MEGX by about 30%. However, in a recent study by Bhise and Dias (2008), 
erythromycin had no effect on the MEGX test. 
Orlando et al. (2004) have recently also investigated the effect of CYP1A2 inhibitor 
fluvoxamine on the pharmacokinetics of intravenous lidocaine. In healthy volunteers, 
fluvoxamine decreased the clearance of lidocaine by 60% and prolonged the t½ by about 
30%. The Cmax and AUC of MEGX were decreased by about 60%. Based on their own 
studies and the in vitro study by Wang et al. (2000), Orlando et al. suggested that CYP1A2 
and CYP3A4 are responsible for approximately two-thirds and one-third of lidocaine 
metabolism, respectively. 
Lidocaine itself has also been reported to act as a competitive inhibitor of CYP1A2 as 
well as a mechanism-based inhibitor of CYP3A4 (Bensoussan et al. 1995, Wei et al. 
1999). Potential clinical consequences of these inhibitory effects remain obscure. 
4.4 Toxicity 
In addition to blocking conduction in nerve cells in the peripheral nervous system, 
lidocaine can interfere with the function of all organs in which conduction or transmission 
of impulses occurs. Thus, like all local anaesthetics, it may have an influence on the 
central nervous system (CNS) and produce direct and indirect cardiovascular effects 
(Mather and Chang 2001). Unintentional toxic blood levels are possible after intra-arterial, 
intravenous or peripheral tissue injections of local anaesthetics. 
The maximum plasma concentration of lidocaine resulting from an accidental 
intravascular injection depends on a number of factors. Clearly, it is directly influenced by 
the total dose of lidocaine injected, the speed and site of injection and whether the 
injection is administered intravenously or intra-arterially. The lungs are an important 
repository for local anaesthetic drugs; plasma concentrations of lidocaine will be much 
higher if the lungs are bypassed (e.g. an accidental intra-arterial injection in the head, face 
or neck region). 
Systemic toxic reactions occur much less frequently when lidocaine is administered to 
peripheral sites than with intravascular injection. A number of factors influence the degree 
of absorption that takes place from the periphery to the central circulation. The most 
important factor is the site of injection, absorption being more rapid in highly vascular 
tissues and less so in poorly perfused ones. The addition of epinephrine to lidocaine 
reduces the rate of absorption, but the magnitude of this reduction can depend on the site 
of injection (Tucker and Mather 1979). 
Systemic toxic reactions to lidocaine are manifested by a progressive spectrum of 
neurological symptoms as blood levels rise. As the plasma concentration of lidocaine 
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approaches systemic toxicity, a typical progression occurs from effects on the CNS to 
effects on the cardiovascular system. However, this pattern of symptomatology may not be 
seen after a rapid intravascular injection. Initial symptoms suggest some form of CNS 
excitation and are often described as a ringing in the ears, a metallic taste in the mouth or a 
tickling sensation or numbness of the tongue and perioral tissues. With increasing blood 
levels of lidocaine, there is progression to motor twitching in the periphery, followed by 
grand mal seizures. These higher blood levels are associated with coma and eventually 
respiratory arrest. At extremely high levels, cardiac arrhythmia or hypotension and 
cardiovascular collapse occur. 
In humans, subjective effects from lidocaine are associated with venous plasma 
concentrations of 3-5 µg/ml. Symptoms of subjective toxicity include light-headedness, 
euphoria, digital paresthaesias, restlessness and drowsiness. Objective toxicity presents 
with nausea, vomiting, tremors, blurred vision, slurred speech, tinnitus, confusion, 
excitement, psychosis and muscular fasciculations or twitching. Objective toxic effects 
occur in conscious subjects at a plasma level higher than 5 µg/ml (at 6-10 µg/ml), but 
seizures and cardiorespiratory depression do not usually occur until plasma concentrations 
exceed 10 µg/ml. Above this level, subjects may become comatose, with respiratory arrest 
and cardiac asystole. Anaesthetized patients do not, however, show signs of toxicity until 
a level of 10 µg/ml is reached, when circulatory depression becomes obvious (Scott et al. 
1972, Tucker and Mather 1979). 
4.5 Clinical use 
Lidocaine has wide range of clinical applications as a local anaesthetic of intermediate 
duration. It is used for local anaesthesia by topical application, infiltration, peripheral 
nerve block and central nerve block. It can also be applied in intravenous regional 
anaesthesia.  
Lidocaine penetrates intact skin poorly, but absorption through mucous membranes 
may be rapid. Lidocaine is used for topical anaesthesia in the oropharyngeal region before 
endoscopic procedures and to treat painful conditions of the mouth and throat. Lidocaine 
can be delivered to the airways by direct spraying or spraying through an endoscope 
(“spray-as-you-go”), and may be used as a viscous solution or a jelly. Lidocaine can be 
inhaled by a nebulizer to reach the lower airways. It can also be injected transtracheally to 
anaesthetize the vocal cords and trachea (Kundra et al. 2000, Xue et al. 2009). For 
example, during a bronchoscopy the maximum safe dosage of lidocaine for topical airway 
anaesthesia has generally been considered to be 4 mg/kg, but even as large a dose as 8.2 
mg/kg has been suggested by the British Thoracic Society (British Thoracic Society 
Bronchoscopy Guidelines Committee, a Subcommittee of Standards of Care Committee of 
British Thoracic Society 2001). For painful conditions of the mouth, lidocaine solution 
can be used as a rinse and then ejected; for pharyngeal pain, the solution is gargled and 
often swallowed. This method is also often used prior to endoscopic procedures before 
other methods of airway anaesthesia. 
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An eutectic mixture of lidocaine and prilocaine is applied as a cream to produce 
surface anaesthesia of the skin or mucous membranes before minor procedures, e.g. 
venipuncture (Gajraj et al. 1994). Another method of dermal delivery includes a 
transdermal patch of lidocaine for the treatment of, for instance postherpetic neuralgia 
(Dworkin et al. 2007). A novel method is an iontophoretic drug delivery system 
incorporating lidocaine and epinephrine, which produces a rapid local anaesthesia for 
venipuncture (Rose et al. 2002). 
A 2% gel of lidocaine can be used for anaesthesia of mucous membranes, especially in 
the urinary tract, where a dose of 60-200 mg is typically applied (Sweetman 2009). 
The dose of lidocaine used for local anaesthesia depends on the site of injection and 
the procedure used. For infiltration anaesthesia, a 0.5% to 1% solution of lidocaine in 
doses varying from 5 to 200 mg (or up to 500 mg with epinephrine) is commonly 
administered. The duration of infiltration anaesthesia can be more or less doubled by the 
addition of epinephrine (usually 5 µg/ml). Epinephrine also decreases peak concentrations 
of lidocaine in blood. For example, in the tumescent technique for liposuction large 
volumes of very dilute lidocaine (0.05-0.1%) and epinephrine are infiltrated into 
subcutaneous tissue to achieve widespread local anaesthesia (Kucera et al. 2006). In these 
procedures, very large lidocaine doses ranging from 35 to 55 mg/kg have been used 
(Kenkel et al. 2004). 
The dosage and concentration of lidocaine in peripheral nerve blocks depend on the 
route. For a brachial plexus block, for example, 225-300 mg as a 1-2% solution is 
recommended, but clinicians often use much larger doses of up to 900 mg (Pälve et al. 
1995, Sweetman 2009). For an intercostal nerve block, 30 mg is given as a 1% solution, 
and for a paracervical block a dose of 100 mg on each side as a 1% solution is 
recommended (Sweetman 2009). 
A hyperbaric solution of 5% lidocaine in glucose is available for spinal anaesthesia. 
Lidocaine, usually at a dose of 50-100 mg, has been used for spinal anaesthesia seemingly 
successfully for decades. It has been especially popular in outpatient spinal anaesthesia 
because of its fast onset and short duration of action. However, recently, a number of 
reports have suggested lidocaine as a possible cause of neurological complications after 
spinal anaesthesia. The incidence of transient radicular irritation in patients who receive 
intrathecal lidocaine has been reported to be as high as one in every third patient (Zaric et 
al. 2005). Accordingly, the use of lidocaine in spinal anaesthesia has decreased lately. 
Epidural block is widely used to provide anaesthesia or analgesia for surgical and 
obstetric procedures. For epidural anaesthesia, 1-1.5 ml of 2% lidocaine solution is needed 
for each dermatome to be anaesthetized (Sweetman 2009). Following injection of 400 mg 
of lidocaine into the lumbal epidural space, peak concentrations of lidocaine average 3-4 
μg/ml (Scott, et al 1972). Continuous epidural infusion of lidocaine at doses of 0.44-0.98 
mg/kg/h for postoperative analgesia produced lidocaine concentrations ranging from 
approximately 1 to 4 μg/ml (Rygnestad et al. 1999). 
A 0.5 % solution of lidocaine in doses of 50-300 mg has been widely used for 
intravenous regional anaesthesia (IVRA). It provides a relatively reliable anaesthesia for 
surgery of extremities; however, analgesia after tourniquet release is short-lived 
(Sweetman 2009). While CNS side-effects can occur with IVRA, after an 80-mg dose of 
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lidocaine and a total tourniquet inflation time of 72 min, Cmax of lidocaine was 1.7 µg/ml 3 
min after tourniquet release (Atanassoff and Hartmannsgruber 2002). 
Lidocaine is commonly used to prevent pain on injection of propofol. It can be 
administered at a dose of 10-40 mg before propofol injection, with or without a tourniquet, 
or it can be mixed with propofol (Picard and Tramer 2000). 
Lidocaine is classified as a class Ib anti-arrhythmic drug and may be used 
intravenously in the treatment of ventricular arrhythmias. Lidocaine suppresses activity of 
depolarized, arrhythmogenic tissues while interfering minimally with the electric activity 
of normal tissues. It is therefore effective in suppressing arrhythmias associated with 
depolarization (e.g. ischaemia), but is relatively ineffective against arrhythmias occurring 
in normally polarized cells (e.g. atrial fibrillation). Lidocaine decreases the duration of the 
action potential and decreases automaticity. Following a bolus dose (normally 1-1.5 
mg/kg), lidocaine has an immediate onset (within minutes) and a brief duration (10-20 
min) of action. Thus, a continuous intravenous infusion of lidocaine (1-4 mg/min) is 
necessary to maintain anti-arrhythmic effects. In emergency situations, lidocaine has also 
been given for arrhythmias by intramuscular injection at a dose of 300 mg, repeated if 
necessary after 60-90 min (Sweetman 2009). 
Earlier, the prophylactic use of lidocaine to suppress ventricular arrhythmias in acute 
myocardial infarction (AMI) was considered the standard of care. However, although 
prophylactic lidocaine reduces the incidence of primarily ventricular fibrillation, it has 
never been shown to decrease mortality. On the contrary, there are increasing concerns 
about the safety of prophylactic lidocaine, and it is no longer recommended in the 
management of patients with AMI (Yadav and Zipes 2004). 
Until 2000, lidocaine was considered to be the anti-arrhythmic drug of choice during 
cardiopulmonary resuscitation. Studies comparing it with amiodarone have displaced it 
from this position, and lidocaine at a dose of 1 mg/kg is now indicated in refractory 
ventricular fibrillation or tachycardia only if amiodarone is unavailable (Nolan et al. 
2005). 
Lidocaine has been shown to be effective in treating peripheral neuropathic pain. 
Systemic lidocaine relieves the symptoms of neuropathic pain in patients with painful 
diabetic neuropathy, postherpetic neuralgia and idiopathic trigeminal neuralgia among 
others (Amir et al. 2006). Topical lidocaine, usually as a transdermal patch of 5% 
lidocaine, is a first-line medication for patients with localized peripheral neuropathic pain, 
e.g. postherpetic neuralgia (Dworkin et al. 2007). Systemic lidocaine may also be of 
benefit in the treatment of central neuropathic pain associated with stroke or spinal cord 
injury (Attal et al. 2000). 
Perioperative systemic lidocaine has preventive effects on postoperative pain and 
opioid consumption after major abdominal surgery (Groudine et al. 1998, Koppert et al. 
2004, Kaba et al. 2007). Continuous intravenous lidocaine infusion accelerates 
postoperative recovery of bowel function and shortens hospital stay (Marret et al. 2008). 
Possibly, some of the beneficial effects of epidural administration of local anaesthetics 
may be caused by anti-inflammatory effects of circulating local anaesthetics (Hollmann 
and Durieux 2000). Conversely, perioperative systemic lidocaine did not offer any 
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beneficial effect on postoperative analgesia and functional recovery after total hip 
arthroplasty (Martin et al. 2008). 
Lidocaine is frequently used intravenously or locally to prevent cardiovascular and 
airway responses during tracheal intubation. Various studies have reviewed the effect of 
lidocaine to blunt these responses. Lidocaine is commonly agreed to blunt cough reflexes 
and dysrhythmias and may even diminish the prolongation of the QT interval induced by 
tracheal intubation (Lev and Rosen 1994, Owczuk et al. 2008). The effects of lidocaine on 
rises in pulse, blood pressure and intracranial and intraocular pressure following intubation 
are somewhat controversial (Miller and Warren 1990, Moeini et al. 2006, Salhi and 
Stettner 2007, Vaillancourt and Kapur 2007). 
Lidocaine has been used intravenously and also intratympanically in the treatment of 
tinnitus (Simpson and Davies 1999). Occasionally, intravenous or intranasal lidocaine has 
been effective in treating various types of severe headache (Matharu et al. 2004). 
Lidocaine has a concentration-dependent effect on seizures. At low concentrations (< 5 
µg/ml), it has anticonvulsant properties, while high concentrations (> 15 µg/ml) often 
result in seizures (DeToledo 2000). Lidocaine has been used to control status epilepticus 
that does not respond to more conventional treatment, especially in children and neonates 
(Hamano et al. 2006). The usual dose is a 1.5-2 mg/kg intravenous bolus, followed by a 3-
4 mg/kg/h infusion (Sweetman 2009). 
Lidocaine, like other local anaesthetics, has potent anti-inflammatory properties. The 
detailed mechanisms of action are not fully understood, but seem to involve a interaction 
with membrane proteins and lipids, thus having an effect at almost every level of the 
inflammatory cascade, including cellular adhesion to the endothelium, transendothelial 
migration, phagocytosis and release of such inflammatory mediators as histamine and 
leukotrienes (Hollmann and Durieux 2000, Fischer et al. 2001, Cassuto et al. 2006). 
Furthermore, lidocaine appears to prevent overactive inflammatory responses without 
impairing host defence or suppressing normal inflammation (Wright et al. 2008). There is 
convincing evidence of these effects in experimental in vitro and in vivo studies, but so far 
clinical use has been limited to selected inflammatory conditions or diseases. For example, 
nebulized lidocaine has a glucocorticoid-sparing effect in the treatment of asthma (Hunt et 
al. 2004). The anti-inflammatory effect of lidocaine seems to be prolonged, continuing 
after serum levels have decreased. 
5 CYP inhibitors evaluated 
5.1 Erythromycin 
Erythromycin, first introduced in 1952, is a macrolide antibiotic widely used in the 
treatment of various bacterial infections. It has mainly been used in infections of the upper 
respiratory tract, skin and soft tissue, especially in patients who are allergic to penicillin. 
As with other macrolides, erythromycin inhibits RNA-dependent protein synthesis of 
sensitive microorganisms (Champers 2006). It is usually bacteriostatic, although 
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bactericidal activity may occur under certain conditions or against specific 
microorganisms. 
Erythromycin has been used extensively in the treatment of various streptococcal and 
staphylococcal infections. Unfortunately, macrolide-resistant strains among these bacteria 
are increasingly detected. Erythromycin has consistent and useful activity against, for 
instance, Mycoplasma pneumoniae and some Gram-negative bacteria such as Chlamydia 
pneumoniae and Bordetella pertussis (Champers 2006). Erythromycin can be used both 
orally and intravenously. The recommended daily dose in adults is 1-2 g, divided into 
three or four doses. However, the use of erythromycin has decreased lately partly due to 
increasing bacterial resistance and to the development of newer macrolides. 
 
Figure 3 Chemical structure of erythromycin. 
Pharmacokinetics 
Erythromycin is well-absorbed from the gastrointestinal tract. The erythromycin base is 
subject to destruction by gastric acid, and therefore, the drug is administered as either 
enterosoluble capsules, as in our study, or in ester form. Erythromycin has a 
bioavailability of about 50% and is 75-90% bound to plasma proteins (Yu et al. 2001). 
The normal serum half-life of erythromycin is 1.4 h, and serum levels are maintained for 6 
h (Alvarez-Elcoro and Enzler 1999). In healthy (Caucasians) volunteers, the Cmax of 
erythromycin was 2.3 mg/l at a tmax of 3.0 h after a single oral dose of 500 mg given as an 
enteric-coated formulation (Yu et al. 2001). Erythromycin is excreted primarily in the bile; 
only 2-5% is excreted unchanged in urine. The primary metabolic pathway is 
demethylation to form N-desmethylerythromycin. This CYP3A4-mediated demethylation 
of erythromycin has been used as a probe reaction to estimate CYP3A4 activity in the 
liver in the erythromycin breath test (ERBT). This test is performed after intravenous 
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administration of labelled erythromycin, which finally generates labelled CO2, which can 
be monitored in the exhalation (Watkins 1994). However, it has recently been discovered, 
that ERBT does not merely reflect CYP activity; hepatic P-glycoprotein might also be an 
important determinant of ERBT (Kurnik et al. 2006). 
Adverse effects 
Erythromycin is a safe antibiotic, and most adverse reactions are non-life-threatening. 
Gastrointestinal symptoms, including nausea, vomiting, abdominal cramps and diarrhoea, 
are the most common adverse effects (Alvarez-Elcoro and Enzler 1999). 
Interactions 
Erythromycin inhibits CYP3A4 and is associated with clinically significant drug 
interactions. It increased the AUC of oral midazolam more than 4-fold and decreased the 
clearance of intravenously administered midazolam by 50% (Olkkola et al. 1993). The 
AUC of zopiclone, another hypnotic, was increased by 80% by erythromycin (Aranko et 
al. 1994). Erythromycin decreased the clearance of alfentanil, a short-acting opioid, by 
25% and prolonged its t½ by approximately 60% (Bartkowski et al. 1989). When 
erythromycin was given together with the histamine-1-antagonist terfenadine, the 
pharmacokinetics of terfenadine was significantly altered, and also electrocardiographic 
changes were seen in subjects who accumulated terfenadine (Honig et al. 1992). The AUC 
values of the anxiolyte buspirone and the cholesterol-lowering drug simvastatin were 6-
fold increased after a pretreatment of erythromycin (Kivistö et al. 1997, Kantola et al. 
1998). Erythromycin increased the AUC and Cmax of sildenafil, an oral drug used in the 
treatment of erectile dysfunction, by 2.8- and 2.6-fold, respectively (Muirhead et al. 2002). 
The plasma concentrations of warfarin and its anticoagulant effect were increased when it 
was co-administered with erythromycin (Weibert et al. 1989). Erythromycin had only a 
minor effect on the pharmacokinetics of intravenous ropivacaine, a long-acting amide-type 
local anaesthetic (Jokinen et al. 2000). 
Recently, the effect of erythromycin on the pharmacokinetics of ximelagatran, an oral 
direct thrombin inhibitor, was investigated in both healthy volunteers and in an in vitro 
model to investigate the interaction mechanism (Eriksson et al. 2006). Erythromycin 
increased the AUC and Cmax of oral ximelagatran by approximately 80% and 70%, 
respectively, and inhibited the P-glycoprotein-mediated transport of ximelagatran. This 
inhibition of P-glycoprotein by erythromycin has also been shown earlier and may partly 
explain the interactions caused by erythromycin (Takano et al. 1998, Schwarz et al. 2000, 
Zhang and Benet 2001). 
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5.2 Itraconazole 
Itraconazole is a triazole antifungal agent that was synthesized in 1980. It inhibits the 
growth of fungi by interfering with a fungal CYP enzyme, 14α-demethylase, thus 
impairing the synthesis of ergosterol, a vital component of the cell membrane (De Beule 
and Van Gestel 2001). Itraconazole is a potent antimycotic drug, particularly because its 
main metabolite, hydroxy-itraconazole, also has clinically significant activity (Isoherranen 
et al. 2004). Itraconazole has a broad spectrum of activity against fungal pathogens, 
including Candida albicans and Aspergillus species (Grant and Clissold 1989). The 
recommended daily dose of itraconazole is from 100 to 400 mg, and the duration of 
treatment varies from one day to one year depending on the mycosis treated. It can also be 
given as a pulse therapy (typically, one week on and three weeks off therapy). 
 
Figure 4 Chemical structure of itraconazole. 
Pharmacokinetics 
Itraconazole is a highly lipophilic weak base, and gastric acidity is needed for its 
dissolution and absorption. A capsule formulation of itraconazole, which has been used 
for many years, is associated with a high degree of variability in absorption. In healthy 
fasting volunteers, the bioavailability of itraconazole is 40%, and it is improved if the drug 
is taken with food (Grant and Clissold 1989). This variability in absorption led to the 
development of an oral solution and intravenous preparation of itraconazole. The oral 
solution had almost 40% higher bioavailability than the capsule formulation after a single 
200-mg dose of itraconazole in healthy volunteers (Willems et al. 2001). 
In blood, itraconazole is 94.9% bound to plasma proteins, mainly albumin, and 4.9% is 
bound to blood cells, leaving only 0.2% in free form. It has a large apparent volume of 
distribution of 11 l/kg. It accumulates in the kidney, liver, bone, stomach, spleen, the 
female genital tract, muscle and keratinous tissues (Grant and Clissold 1989). 
Itraconazole is extensively metabolized in the liver to produce more than 30 
metabolites. Hydroxy-itraconazole, the major metabolite, reaches higher plasma 
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concentrations than the parent agent. The primary rates of excretion are via bile and urine 
as metabolites (De Beule and Van Gestel 2001). Elimination of itraconazole is biphasic. 
The t1/2 is approximately 20 h after a single dose, but is prolonged to 30 h during steady 
state (Grant and Clissold 1989). This indicates that the metabolism of itraconazole is 
saturated with clinical doses. 
Adverse effects 
Itraconazole is generally well-tolerated, with most adverse effects being minor and 
reversible. The most common adverse effects are gastrointestinal disturbances, dizziness, 
pruritus and headache (Grant and Clissold 1989). A mild asymptomatic elevation in 
hepatic enzymes is seen in 1-5% of patients using itraconazole continuously, and in 1.7-
2% of patients receiving pulse therapy. The increased enzyme levels usually return to 
normal following discontinuation of therapy or even spontaneously (Gupta et al. 2002). 
Interactions 
Because itraconazole is a potent inhibitor of CYP3A4 both in vitro and in vivo, 
itraconazole co-administration with a CYP3A4 substrate can result in a clinically 
significant drug interaction (Wang et al. 1999b, Dresser et al. 2000). Furthermore, the 
metabolites of itraconazole can be as potent inhibitors of CYP3A4 as itraconazole itself 
(Isoherranen et al. 2004, Templeton et al. 2008). Consequently, itraconazole can greatly 
increase the plasma concentrations of many drugs, like terfenadine (Honig et al. 1993), 
midazolam (Olkkola et al. 1994), triazolam (Varhe et al. 1994), felodipine (Jalava et al. 
1997b), buspirone (Kivistö et al. 1997), dexamethasone (Varis et al. 2000) and both oral 
and intravenous methylprednisolone (Varis et al. 1998, Varis et al. 1999). For example, 
itraconazole increased the Cmax of oral midazolam over 3-fold and the AUC over 10-fold 
(Olkkola et al. 1994). The clearance of intravenous midazolam was decreased 69% by 
concomitant itraconazole (Olkkola et al. 1996). Pretreatment with itraconazole reduced the 
clearance of both enantiomers of intravenous bupivacaine, an amide-type local 
anaesthetic, by approximately 20-25% (Palkama et al. 1999). Itraconazole had no 
significant effect on the pharmacokinetic parameters of intravenous ropivacaine, another 
amide-type local anaesthetic, although it inhibited the CYP3A4-mediated formation of 
pipecoloxylidide from ropivacaine (Jokinen et al. 2001). This lack of interaction with 
ropivacaine suggests that CYP1A2 has a major role in its metabolism. Finally, 
itraconazole increased the AUC of inhaled glucocorticoid budesonide by about 4-fold, 
resulting in suppression of cortisol production (Raaska et al. 2002). 
Itraconazole is also a potent inhibitor of P-glycoprotein (Wang et al. 2002a). Thus, it 
can increase plasma concentrations of P-glycoprotein subjects even when they are not 
significantly metabolized. For example, significant interactions have been reported 
following co-administration of itraconazole with celiprolol (Lilja et al. 2003), vincristine 
(Bermúdez et al. 2005) or digoxin (Jalava et al. 1997a). Also the drastic effect of 
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itraconazole on the pharmacokinetics of the cholesterol-lowering drug lovastatin may be 
the result of inhibition of both P-glycoprotein and CYP3A4 (Neuvonen and Jalava 1996, 
Kivistö et al. 1998). 
5.3 Fluvoxamine 
Fluvoxamine is an antidepressant drug that belongs to the selective serotonin reuptake 
inhibitor (SSRI) group. It is used widely in the treatment of depression, with daily doses 
ranging from 50 to 300 mg. Other potential therapeutic indications include obsessive-
compulsive disorder, anxiety, panic disorder and social phobia (Perucca et al. 1994, 
Figgitt and McClellan 2000). 
 
Figure 5 Chemical structure of fluvoxamine. 
Pharmacokinetics 
Fluvoxamine is almost completely, albeit slowly, absorbed from the gastrointestinal tract, 
but the oral bioavailability is only ~ 50% (Perucca et al. 1994, van Harten 1995). After 
repeated therapeutic doses, fluvoxamine exhibits non-linear pharmacokinetics. A Cmax of 
about 70 µg/l is reached within 2-8 h when fluvoxamine is administered at a daily dose of 
100 mg, with a steady state attained in about 10 days. Fluvoxamine has a volume of 
distribution of 25 l/kg and is only 77% bound to plasma proteins (Figgitt and McClellan 
2000). It is extensively metabolized, primarily by the hepatic CYP enzymes CYP2D6 and 
CYP1A2, to inactive metabolites (Carrillo et al. 1996, Spigset et al. 2001). Only 3% of 
orally administered fluvoxamine is excreted unchanged in urine (Figgitt and McClellan 
2000). The t1/2 of fluvoxamine ranges from 15 to 20 h (Perucca et al. 1994). 
Adverse effects 
Fluvoxamine is generally well-tolerated and serious adverse effects are rare. The most 
common adverse effect is nausea; other, less common side-effects include somnolence, 
asthenia, headache, dry mouth and sleep disorders (Figgitt and McClellan 2000). 
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Interactions 
Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 (Rasmussen et al. 1995, Yao 
et al. 2003), but it may also inhibit CYP3A4, CYP2C9 and CYP2D6 (von Moltke et al. 
1995, Kashuba et al. 1998, Hemeryck et al. 1999). It has the potential, therefore, to modify 
the pharmacokinetics of many drugs metabolized by these routes. Fluvoxamine 
considerably increases the plasma concentrations of CYP1A2 substrate drugs such as 
caffeine (Christensen et al. 2002), theophylline (Yao et al. 2001), tacrine (Larsen et al. 
1999), clozapine (Fabrazzo et al. 2000) and the local anaesthetic ropivacaine (Jokinen et 
al. 2000). Coadministration of fluvoxamine produces moderate increases in the AUC of 
such CYP3A4 substrates as alprazolam and buspirone (Fleishaker and Hulst 1994, 
Lamberg et al. 1998). Fluvoxamine also has a moderate impact on the pharmacokinetics of 
the CYP2C9 substrates tolbutamide and glimepiride (Madsen et al. 2001, Niemi et al. 
2001). Fluvoxamine is an effective inhibitor of CYP2C19 and has a marked effect on the 
pharmacokinetics of omeprazole and (S)-mephenytoin (Christensen et al. 2002, Yao et al. 
2003). Recently, fluvoxamine was found to have a mild effect on the pharmacokinetics of 
the CYP2C8 substrate rosiglitazone (Pedersen et al. 2006). 
Fluvoxamine is only an intermediate inhibitor of P-glycoprotein in vitro, and in 
healthy volunteers it had no significant effect on the pharmacokinetics of digoxin (Ochs et 
al. 1989, Weiss et al. 2003). 
5.4 Ciprofloxacin 
Ciprofloxacin is a broad-spectrum fluoroquinolone antimicrobial agent showing high 
activity, especially against Gram-negative bacteria (van Bambeke et al. 2005). The 
mechanism of action of its rapid bactericidical effect involves interacting with DNA 
gyrase and topoisomerase IV enzymes, leading to cleavage of bacterial DNA (Hooper 
1999). The usual adult oral dose ranges from 250 mg to 750 mg twice daily. 
 
 
Figure 6 Chemical structure of ciprofloxacin. 
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Pharmacokinetics 
The oral bioavailability of ciprofloxacin is approximately 70%. After single oral doses of 
250-750 mg in healthy volunteers, Cmax values ranging from 0.8 to 3.9 mg/l are reached 
within 1-2 h (Davis et al. 1996). Ciprofloxacin has a volume of distribution of 1.7-2.5 l/kg 
and is only 20-40% bound to plasma proteins. It is widely distributed in the body, and 
tissue penetration is good in most tissues, with the exception of cerebrospinal fluid. 
Ciprofloxacin is eliminated mainly in unchanged form, with about one-third of the dose 
being metabolized. Its t1/2 is between 3 and 5 h (Aminimanizani et al. 2001). 
Adverse effects 
The adverse effects of ciprofloxacin are generally mild and reversible, and most often 
involve the gastrointestinal tract, CNS or skin. The most common side-effects are 
gastrointestinal symptoms, particularly nausea, vomiting and diarrhoea. CNS symptoms, 
including headache, dizziness, tremor and restlessness, are less common. Skin effects, 
such as phototoxicity, may also be seen (Davis et al. 1996). Because of the risk of 
chondrotoxicity, ciprofloxacin is not recommended for use in children (van Bambeke et al. 
2005). Finally, ciprofloxacin is associated with tendon disorders, especially in elderly 
patients (van der Linden et al. 2002). 
Interactions 
Ciprofloxacin is a moderate inhibitor of CYP1A2 (Fuhr et al. 1992, Bertz and Granneman 
1997). It inhibits the metabolism of such CYP1A2 substrates as theophylline (Batty et al. 
1995), caffeine (Nicolau et al. 1995), clozapine (Raaska and Neuvonen 2000) and 
ropivacaine (Jokinen et al. 2003). 
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AIMS OF THE STUDY 
Lidocaine is a widely used local anaesthetic agent that is administered by injection or local 
application. It is also used intravenously in the prevention and treatment of ventricular 
arrhythmias. Lidocaine is eliminated mainly by metabolism, with only trace amounts 
being excreted unchanged in urine. One of the major metabolites is MEGX. Lidocaine is 
also metabolized via hydroxylation to 3-OH-lidocaine. At the time that this study 
commenced, CYP3A4 was thought to be mainly responsible for the formation of MEGX, 
and CYP1A2 for the production of 3-OH-lidocaine. 
CYP enzyme-related drug interactions affect the pharmacokinetics of many drugs. 
Erythromycin and itraconazole are known inhibitors of CYP3A4, and ciprofloxacin and 
fluvoxamine inhibit CYP1A2 (Pelkonen et al. 2008). Previous studies have demonstrated 
that non-specific inhibitors of CYP enzymes, e.g. cimetidine and ranitidine, have some 
effect on lidocaine pharmacokinetics, but the effect of specific CYP inhibitors remain 
obscure. 
Specific aims of this study were as follows: 
 
1. To evaluate the effect of strong inhibitors of CYP3A4 on the 
pharmacokinetics of lidocaine (Studies I-III). 
2. To determine the effect of route of administration of lidocaine when 
CYP3A4 is inhibited (Studies I-III). 
3. To investigate the effect of inhibiting both CYP1A2 and CYP3A4 on the 
pharmacokinetics of lidocaine administered intravenously or orally (Studies IV and V). 
4. To elucidate the role of CYP1A2 in the metabolism of lidocaine and to 
examine the interaction potential of ciprofloxacin with intravenous lidocaine (Study VI). 
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MATERIALS AND METHODS 
1 Subjects 
All 34 subjects (17 females, 17 males) were healthy volunteers. Before being accepted 
into the studies, volunteers were ascertained to be healthy by medical history, clinical 
examination and a 12-lead electrocardiogram. None of the participants was on continuous 
medication, except for six female subjects using oral contraceptive steroids. Detailed 
characteristics of the volunteers are presented in Table 2. 
 
Table 2. Characteristics of healthy volunteers in Studies I-VI 
Study  Subjects 
(f/m) 
Age, 
years* 
Weight, 
kg* 
No. of women using 
contraceptives 
I 9 (4/5) 22 (18-25) 69 (55-80) 4 
II 9 (4/5) 23 (21-25) 72 (61-83) 2 
III 10 (5/5) 24 (22-25) 69 (60-80) 3 
IV 9 (6/3) 23 (19-27) 68 (58-90) 1 
V 8 (3/5) 24 (21-27) 68 (50-83) 1 
VI 9 (6/3) 24 (21-29) 72 (45-95) 1 
Values indicated with an asterisk are mean (range). f/m = female/male. 
2 Study protocol 
2.1 Design 
The studies were performed between April 1996 and May 1999 at the Department of 
Anaesthesiology and Intensive Care Medicine and the Department of Clinical 
Pharmacology, University of Helsinki. All studies were randomized, double-blinded, 
placebo-controlled cross-over studies in two or three phases with a 2- to 4-week wash-out 
interval. The study designs are summarized below and in Table 3. 
In Studies I, IV and VI, the volunteers fasted for 1-2 h before the lidocaine infusion. 
They had standard meals 3 and 6 h after the infusion. In Studies II, III and V, the 
volunteers fasted for 4 h before lidocaine administration and had standard meals 3 and 6 h 
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afterwards. Ingestion of alcohol, coffee, tea, cola beverages and grapefruit juice was not 
allowed on the test days, nor was smoking permitted. 
Study I 
Nine volunteers were given orally either erythromycin 500 mg three times a day (Erymax, 
Astra, Sweden), itraconazole 200 mg once daily (Sporanox, Janssen Pharma, Belgium) or 
placebo three times a day for four days. The dose of 1.5 mg/kg of intravenous lidocaine 
(Lidokainklorid 4 mg/ml, Kabi-Pharmacia, Sweden) was given on day 4, with the infusion 
lasting for 60 min. Lidocaine was given 1 h after the administration of erythromycin, 
itraconazole or placebo. 
Study II 
As in Study I, the nine volunteers were given orally either erythromycin 500 mg three 
times a day (Erymax, Astra, Sweden), itraconazole 200 mg once daily (Sporanox, Janssen 
Pharma, Belgium) or placebo three times a day for four days. On day 4, each subject 
ingested a single dose of 1 mg/kg of oral lidocaine (Xylocain 5 mg/ml, Astra, Sweden) 
one hour after the administration of erythromycin, itraconazole or placebo. 
Study III 
Ten volunteers were given orally, once daily, either itraconazole 200 mg (Sporanox, 
Janssen Pharma, Belgium) or placebo for four days. The dose of 1.5 mg/kg of lidocaine 
(Lidocain 40 mg/ml, Orion, Finland) was given on day 4 one hour after the administration 
of itraconazole or placebo. Lidocaine was administered using a disposable nebulizer 
(Micro Mist, Hudson RCI, CA, USA) powered by oxygen at a flow of 8 l/min. The 
subjects breathed the lidocaine aerosol through a mouthpiece until nebulization of the 
lidocaine solution was complete (10 min). A nasal clip was not used. 
Study IV 
Nine volunteers were given either fluvoxamine 100 mg (Fevarin, Solvay Duphar, Holland) 
once a day and placebo thrice daily, or fluvoxamine 100 mg once a day and erythromycin 
500 mg (Ery-Max, Astra, Sweden) thrice daily, or the corresponding placebos. 
Erythromycin was given for six days and fluvoxamine for five days before lidocaine. On 
day 6, the dose of 1.5 mg/kg of intravenous lidocaine (Lidokainklorid 4 mg/ml, Kabi-
Pharmacia, Sweden) was given over 60 min. Lidocaine infusion was started one hour after 
the administration of erythromycin 500 mg (or placebo) or 9 h after the last 100-mg dose 
of fluvoxamine (or placebo). 
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Study V 
Eight volunteers were given either fluvoxamine 100 mg (Fevarin, Solvay Duphar, 
Holland) once a day and placebo thrice daily, or fluvoxamine 100 mg once a day and 
erythromycin 500 mg (Ery-Max, Astra, Sweden) thrice daily, or the corresponding 
placebos. Erythromycin was given for six days and fluvoxamine for five days before 
lidocaine. On day 6, each subject ingested a single dose of 1 mg/kg of oral lidocaine 
(Xylocain 5 mg/ml, Astra, Sweden). Lidocaine was given one hour after the 
administration of erythromycin 500 mg (or placebo), or 13 h after the last 100-mg dose of 
fluvoxamine (or placebo). 
Study VI 
Nine volunteers were randomized to receive either ciprofloxacin 500 mg (Ciproxin, Bayer, 
Germany) or placebo twice daily orally for 2.5 days. On day 3, 1.5 mg/kg of lidocaine 
(Lidocard 20 mg/ml, Orion, Finland) was administered in 60 min. The lidocaine infusion 
was initiated one hour after the administration of ciprofloxacin or placebo. 
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Table 3. Study designs (I-VI) 
Study Pretreatment  Lidocaine Wash-out
  Drug Duration Dose Timing   
         
I Erythromycin 500 mg x 3 
Itraconazole 200 mg x 1 
Placebo 
4 days 1.5 mg/kg 60 min i.v. inf  
day 4 
1 h after pre 
3 weeks 
           
II Erythromycin 500 mg x 3 
Itraconazole 200 mg x 1 
Placebo 
4 days 1 mg/kg p.o. day 4 
1 h after pre 
3-4 weeks 
           
III Itraconazole 200 mg x 1 
Placebo 
4 days 1.5 mg/kg inhaled day 4 
1 h after pre 
4 weeks 
           
IV Fluvoxamine 100 mg x 1 
+ placebo 
Fluvoxamine 100 mg x 1 
+ Erythromycin 500 mg x 3 
Placebo 
5 days 
 
 
6 days 
1.5 mg/kg 60 min i.v. inf  
day 6 
9 h after fluvo 
1 h after erythromycin 
2 weeks 
      
V Fluvoxamine 100 mg x 1 
 + placebo 
Fluvoxamine 100 mg x 1 
 + Erythromycin 500 mg x 3 
Placebo 
5 days 
 
 
6 days 
1 mg/kg p.o. day 6 
13 h after fluvo 
1 h after erythromycin 
4 weeks 
      
VI Ciprofloxacin 500 mg x 2 
Placebo 
2.5 days 1.5 mg/kg 60 min i.v. inf 
day 3 
1 h after pre 
4 weeks 
2.2 Blood sampling 
On each study day, a cubital vein was cannulated with a plastic cannula and kept patent 
with an obturator. In Studies I, IV and VI, the samples were taken from the arm 
contralateral to that used for the administration of intravenous lidocaine. Timed blood 
samples were drawn into 10-ml EDTA tubes in Studies I, IV and VI just before the 
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administration of lidocaine and at 30 and 60 min during the 60-min infusion. After the 
infusion, blood was sampled at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 10 h. In Studies II, III and V, 
samples were taken just before the administration of lidocaine and at 0.5, 1, 1.5, 2, 3, 4, 5, 
6, 8 and 10 h afterwards. Plasma was separated within 30 min and stored at -40°C until 
analysis. 
2.3 Determination of plasma drug concentrations 
Lidocaine 
Concentrations of lidocaine were analysed with gas chromatography using etidocaine as 
an internal standard (Lorec et al. 1994, Demedts et al. 1996). The limit of quantification of 
the method was 2 ng/ml in Studies I-IV and 0.1 ng/ml in Studies V and VI. The coefficient 
of variation (CV) for lidocaine was 2.1% at 98.0 ng/ml (n=15) in Studies I and II, 1.5% at 
99.8 ng/ml (n=8) in Study III, 2.9% at 98.5 ng/ml (n=7) in Study IV, 1.7% at 75.7 ng/ml 
(n=7) in Study V and 4.7% at 80.7 ng/ml (n=4) in Study VI. 
MEGX 
Concentrations of MEGX were analysed with gas chromatography using etidocaine as an 
internal standard (Lorec et al. 1994, Demedts et al. 1996). The limit of quantification of 
the method was 2 ng/ml in Studies I-IV, 0.05 ng/ml in Study V and 0.1 ng/ml in Study VI. 
The CV for MEGX was 4.1% at 95.3 ng/ml (n=15) in Studies I and II, 4.7% at 100.3 
ng/ml (n=7) in Study III, 4.0% at 98.9 ng/ml (n=7) in Study IV, 4.3% at 80.1 ng/ml (n=7) 
in Study V and 5.7% at 84.1 ng/ml (n=7) in Study VI. 
3-OH-lidocaine 
In Studies V and VI, concentrations of 3-OH-lidocaine were analysed with gas 
chromatography using etidocaine as an internal standard (Lorec et al. 1994, Demedts et al. 
1996). The limit of quantification of the method was 0.03 ng/ml in Study V and 0.05 
ng/ml in Study VI. The CV for 3-OH-lidocaine was 4.5% at 0.8 ng/ml (n=7) in Study V 
and 12.0% at 0.8 ng/ml (n=4) in Study VI. 
Erythromycin 
Concentrations of erythromycin in Studies I, II, IV and V were measured with high-
performance liquid chromatography (HPLC) using roxithromycin as an internal standard 
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(Laakso et al. 1990). The sensitivity of the method was 0.2 mg/l, and the CV was 3% at 
4.97 mg/l (n=9). 
Itraconazole 
Itraconazole was quantified by HPLC using a method modified from Allenmark et al. 
(1990). The limit of quantification was 10 ng/ml. The CV was 1.2% at 474 ng/ml (n=9) in 
Study I, 1.2% at 472 ng/ml (n=9) in Study II and 4.6% at 192 ng/ml (n=12) in Study III. 
Fluvoxamine 
Fluvoxamine concentrations in Studies IV and V were determined with HPLC using 
haloperidol as an internal standard (van der Meersch-Mougeot and Diquet 1991). The 
limit of quantification was 10.0 ng/ml, and the CV was 9.2% at 16.9 ng/ml (n=7) and 
4.5% at 85.7 ng/ml (n=7). 
Ciprofloxacin 
Ciprofloxacin was quantified by liquid chromatography tandem mass spectrometry with 
electrospray ionization, using ofloxacin as an internal standard (Volmer et al. 1997). The 
CV was 7.6% at 27.4 ng/ml (n=3) and 3.7% at 794.7 ng/ml (n=3). 
2.4 Pharmacokinetic calculations 
The peak plasma drug concentrations (Cmax) and the corresponding times (tmax) of 
lidocaine, MEGX and 3-OH-lidocaine (in Studies V and VI) were taken from the original 
plasma concentration data. Specifically, tmax was obtained for lidocaine in Studies II, III 
and V, for MEGX in all studies, and for 3-OH-lidocaine in Studies V and VI. In all 
studies, the terminal log-linear phase of the drug concentration-time curve was visually 
identified, and the elimination rate constant (kel) was determined by regression analysis. 
The elimination half-life (t½) was calculated from t½=ln2/kel. The areas under the 
concentration-time curves (AUC) were calculated using the linear trapezoidal rule when 
successive concentration values increased, and the logarithmic trapezoidal rule when 
successive concentration values decreased after the peak concentration value. AUC was 
extrapolated to infinity by using the respective kel value. In Studies I, IV and VI, the 
values for plasma clearance (CL) and steady-state volume of distribution (Vss) of lidocaine 
were calculated using non-compartmental methods. The calculations for the Vss of 
lidocaine were formulated to take into account the time of infusion, i.e., 
 
Vss = (k0 T · AUMC)/AUC2 – k0 T2/(2 · AUC), 
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in which k0 is the infusion rate, T the duration of the infusion and AUMC the area under 
the first moment of the plasma concentration-time curve. 
We also calculated the ratio of AUC of MEGX and 3-OH-lidocaine (Studies V and VI) 
to that of lidocaine (AUC ratio). 
The pharmacokinetic parameters were calculated using the pharmacokinetic program 
MK-Model, version 5.0 (Biosoft, Cambridge, UK). 
2.5 Safety assessment 
Studies I, IV and VI were carried out in a postanaesthesia care unit. During the infusion of 
lidocaine and for 2 h afterwards, a 3-lead ECG of the subjects was monitored 
continuously. 
2.6 Statistical methods 
Power analysis was used to determine the number of volunteers needed in each study. 
Based on previous studies (Tucker and Mather 1979), the sample size was calculated to 
demonstrate a 25% difference in area under the lidocaine plasma concentration-time 
curve, and with a chosen power of 0.80 and at a significance level of 0.05. 
Balanced Latin square randomization was used to obtain validity and safety in study 
designs. The assignments for randomization were generated by the Pharmacy of Helsinki 
University Central Hospital, which arranged for the pretreatment drug and matched 
placebo capsules in coded envelopes to be delivered to the volunteers. 
In Studies I, IV and V, consisting of three phases, analysis of variance (ANOVA) was 
used to determine the contribution of each treatment to overall variance. A posterior 
testing was done with Tukey’s test. In Study II, because of high standard deviations in 
AUC values, data were analysed by the Friedman's two-way analysis of variance; a 
posterior testing was done with the Wilcoxon signed-ranks test. In Studies III and VI, the 
pharmacokinetic variables between the two phases were compared with Student’s t-test for 
paired data. However, the values for tmax were compared with the Wilcoxon signed-ranks 
test. 
Differences were considered to be significant if P < 0.05. Results were generally 
expressed as means ± standard deviation (SD); except in some figures, means ± standard 
error of the means (SEM) were used for clarity. In Study III, we also calculated the 95% 
confidence intervals for major differences between the phases, as requested by the editor 
of Basic & Clinical Pharmacology & Toxicology. 
Data were analysed with the statistical program Systat for Windows, version 7.0 
(SPSS, Chicago, IL, USA). 
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2.7 Ethical considerations 
All study protocols were approved by the Ethics Committee of the Department of Surgery, 
Helsinki University Central Hospital, Helsinki, as well as by the Finnish National Agency 
for Medicines. All subjects received both oral and written information and gave their 
written informed consent before entering the studies. 
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RESULTS 
1 Effect of itraconazole on the pharmacokinetics of intravenous 
and oral lidocaine 
A 4-day pretreatment with itraconazole 200 mg once daily had no effect on the 
pharmacokinetics of intravenous lidocaine. The AUC of lidocaine was 1902 ± 405 
ng·h/ml during placebo treatment and 2211 ± 560 ng·h/ml during itraconazole treatment 
and the Cmax of lidocaine was 719 ± 138 and 785 ± 250 ng/ml, respectively. When 
lidocaine was administrated orally, the mean AUC of lidocaine increased by 75% (P < 
0.05) and the Cmax by 55% (P < 0.05). 
After oral lidocaine, itraconazole prolonged the t½ of MEGX from 2.3 ± 0.2 h to 2.6 ± 
0.4 h (P < 0.05) and decreased the ratio of the AUC of MEGX to that of lidocaine by 32% 
(P < 0.05). 
At the time of lidocaine administration, the mean concentration of itraconazole was 
155 ± 75 ng/ml (332 ± 246 ng/ml at end of lidocaine infusion) in Study I and 170 ± 77 
ng/ml (306 ± 167 ng/ml one hour after oral administration) in Study II. 
2 Effect of itraconazole on the pharmacokinetics of inhaled 
lidocaine 
Itraconazole 200 mg once daily did not affect the plasma concentrations of inhaled 
lidocaine or its metabolite MEGX. The AUC of lidocaine was 166 ± 66 ng·h/ml during 
placebo and 173 ± 60 ng•h/ml during itraconazole and the Cmax of lidocaine was 69 ± 24 
and 71 ± 24 ng/ml, respectively. The mean concentration of itraconazole at the time of 
lidocaine administration was 165 ± 72 ng/ml. 
3 Effect of erythromycin on the pharmacokinetics of intravenous 
and oral lidocaine 
Compared with placebo, a 4-day pretreatment with erythromycin 500 mg three times daily 
prolonged the t½ of intravenous lidocaine from 2.5 ± 0.6 h to 2.9 ± 0.7 h (P < 0.05). When 
lidocaine was administrated orally, the mean AUC of lidocaine increased by 50% (P < 
0.05) and the Cmax by 40% (P < 0.05). The t½ of oral lidocaine was longer during 
erythromycin (2.6 ± 0.5 h) than during itraconazole pretreatment (2.2 ± 0.4 h; P < 0.05). 
After both intravenous and oral lidocaine, erythromycin increased the Cmax (P < 0.05) 
and the AUC (P < 0.01) of MEGX, and the AUCMEGX ratio (P < 0.05) by 40-70% 
compared with placebo and itraconazole. After oral administration of lidocaine, the t½ of 
MEGX was prolonged from 2.3 ± 0.2 h to 2.6 ± 0.4 h compared with placebo (P < 0.05). 
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The mean concentration of erythromycin at the end of lidocaine infusion was 2.0 ± 1.3 
mg/l and one hour after oral administration 2.7 ± 1.6 mg/l. When lidocaine was 
administered intravenously, a linear correlation (r=0.89; P < 0.01) existed between the 
relative changes in MEGX concentrations and the area under the erythromycin 
concentration-time curve. 
4 Effect of fluvoxamine on the pharmacokinetics of intravenous 
and oral lidocaine 
A 5-day pretreatment with fluvoxamine 100 mg once daily reduced the mean CL of 
intravenous lidocaine by 41% (P < 0.01) and prolonged the t½ of lidocaine from 2.6 ± 0.4 
h to 3.5 ± 0.7 h (P < 0.01). The mean AUC of lidocaine increased 1.7-fold (range 1.4-2.4; 
P < 0.01). After oral administration of lidocaine, the mean AUC of lidocaine increased 3-
fold (range 2.1-7.4; P < 0.001) and the Cmax 2.2-fold (range 1.2-4.8; P < 0.05). 
Fluvoxamine decreased the Cmax of MEGX by 65% (P < 0.001) and the AUC of 
MEGX by 54% (P < 0.001). The t½ was prolonged from 3.4 ± 0.8 h to 4.6 ± 1.2 h (P < 
0.05). The ratio of the AUC of MEGX to that of lidocaine was decreased by 73% (P < 
0.001) by fluvoxamine. When lidocaine was taken orally, fluvoxamine decreased the Cmax 
of MEGX by 47% (P < 0.001) and the AUC of MEGX by 26% (P < 0.05). The ratio of the 
AUC of MEGX to that of lidocaine was decreased by 76% (P < 0.001). 
After oral administration of lidocaine, fluvoxamine prolonged the t½ of 3-OH-lidocaine 
from 2.8 ± 0.6 h to 3.7 ± 1.2 h (P < 0.05). The ratio of the AUC of 3-OH-lidocaine to that 
of lidocaine was decreased by 75% (P < 0.001). 
During the fluvoxamine phase the mean concentration of fluvoxamine immediately 
before the administration of lidocaine infusion was 56 ± 22 ng/ml and before oral 
administration 47 ± 24 ng/ml. 
5 Effect of the combination of erythromycin and fluvoxamine on 
the pharmacokinetics of intravenous and oral lidocaine 
During pretreatment with fluvoxamine 100 mg once daily for 5 days combined with 
erythromycin 500 mg three times daily for 6 days, the mean CL of intravenous lidocaine 
was 53% smaller than during placebo (P < 0.001) and 21% smaller than during 
fluvoxamine alone (P < 0.05). The t½ of lidocaine (4.3 ± 0.8 h) was significantly longer 
during the combination phase than during the placebo (2.6 ±0.4 h; P < 0.001) or 
fluvoxamine phase (3.5 ± 0.7 h; P < 0.01). The mean AUC of intravenous lidocaine 
increased 2.3-fold (range 1.8-3.7; P < 0.01) and the Cmax 1.4-fold (range 1.0-2.4; P < 0.05). 
After oral administration of lidocaine, the mean AUC of lidocaine increased 3.6-fold 
(range 1.7-9.4; P < 0.001) and the Cmax 2.5-fold (range 1.2-5.1; P < 0.05). The t½ of oral 
lidocaine (3.8 ± 1.2 h) was significantly longer during the combination phase than during 
the placebo (2.4 ± 0.4 h; P < 0.001). 
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The combination of fluvoxamine and erythromycin decreased the Cmax of MEGX by 
54% (P < 0.001) and the AUC of MEGX by 26% (P < 0.05). However, the combination of 
fluvoxamine and erythromycin decreased the AUC of MEGX less than fluvoxamine alone 
(P < 0.05). The t½ was prolonged from 3.4 ± 0.8 h to 5.4 ± 2.2 h (P < 0.01). The ratio of 
the AUC of MEGX to that of lidocaine was decreased by 68% (P < 0.001) by fluvoxamine 
and erythromycin. When lidocaine was taken orally, the combination of fluvoxamine and 
erythromycin decreased the Cmax of MEGX by 29% (P < 0.01). The ratio of the AUC of 
MEGX to that of lidocaine was decreased by 65% (P < 0.01). 
After oral administration of lidocaine, the combination of fluvoxamine and 
erythromycin prolonged the t½ of 3-OH-lidocaine from 2.8 ± 0.6 h to 3.8 ± 0.6 h (P < 
0.01). The ratio of the AUC of 3-OH-lidocaine to that of lidocaine was decreased by 75% 
(P < 0.001). 
When lidocaine was administrated intravenously, the mean plasma fluvoxamine 
concentration just before the administration of lidocaine infusion was 56 ± 22 ng/ml 
during fluvoxamine treatment and 51 ± 28 ng/ml during the combined treatment with 
erythromycin and fluvoxamine. The corresponding concentration of erythromycin was 1.6 
± 0.6 mg/l during the combined treatment. When lidocaine was given orally, the mean 
plasma concentration of fluvoxamine before lidocaine administration was 47 ± 24 ng/ml 
during the fluvoxamine phase and 34 ± 20 ng/ml during the combination of fluvoxamine 
and erythromycin. The mean plasma concentration of erythromycin at 0.5 h after the 
ingestion of lidocaine was 1.8 ± 1.6 mg/l. 
When lidocaine was administered intravenously, the multiple linear regression model, 
which included fluvoxamine and erythromycin concentrations as independent variables, 
was able to predict the observed change in the AUC of lidocaine (r=0.471; P < 0.05).  
6 Effect of ciprofloxacin on the pharmacokinetics of intravenous 
lidocaine 
Compared with placebo, a 2.5-day pretreatment with ciprofloxacin 500 mg twice daily 
increased the mean Cmax and AUC of lidocaine by 12% (P < 0.05) and 26% (P < 0.01), 
respectively. The mean plasma CL of lidocaine was reduced by 22% (P < 0.01) and its t½ 
prolonged by 7% (P < 0.01) by ciprofloxacin. 
Ciprofloxacin decreased the Cmax of MEGX by 40% (P < 0.01). The AUC of MEGX 
was decreased by 21% (P < 0.01), and the t½ was prolonged by 34% (P < 0.05). The ratio 
of the AUC of MEGX to that of lidocaine was decreased by 40% (P < 0.001) by 
ciprofloxacin.  
Ciprofloxacin decreased the Cmax of 3-OH-lidocaine by 22% (P < 0.05) and its AUC 
by 14% (P < 0.01). The tmax and t½ of 3-OH-lidocaine were not significantly affected. 
However, the ratio of the AUC of 3-OH-lidocaine to that of lidocaine was decreased by 
35% (P < 0.001) by ciprofloxacin. 
The mean ciprofloxacin plasma concentration was 655 ng/ml before the administration 
of lidocaine and 288 ng/ml at 10 h after the infusion. 
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7 Summary of results 
The results of the CYP1A2 and CYP3A4 inhibitor-induced changes in the 
pharmacokinetics of lidocaine are summarized in Figures 7-11 and Table 4. All of the 
results summarized below are statistically significant. 
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Figure 7 Mean clearance (CL) of intravenous lidocaine (Liv) after pretreatment with 
itraconazole (Itra), erythromycin (Ery), fluvoxamine (Flu), fluvoxamine plus 
erythromycin (FE) and ciprofloxacin (Cipr) presented as percentages of the 
corresponding values during the placebo phase. 
7.1 Effect of CYP3A4 inhibitors 
Itraconazole and erythromycin did not affect the pharmacokinetics of intravenous 
lidocaine, but erythromycin increased the Cmax and the AUC of MEGX, and the AUC ratio 
of MEGX by 40-70% compared with placebo and itraconazole. Erythromycin also slightly 
prolonged the t½ of lidocaine. Moreover a linear correlation existed between the relative 
changes in MEGX concentrations and the area under the erythromycin concentration-time 
curve. 
When lidocaine was taken orally, both erythromycin and itraconazole increased the 
Cmax and the AUC of lidocaine by 40-70%. Compared with placebo and itraconazole, 
erythromycin increased the Cmax and the AUC of MEGX by 40-60%. Both CYP3A4 
inhibitors slightly prolonged the t½ of MEGX. 
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The pharmacokinetics of inhaled lidocaine was unaffected by concomitant 
administration of itraconazole. 
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Figure 8 Mean areas under the concentration-time curves (AUC) of either intravenous 
lidocaine (Liv) or oral lidocaine (Lpo) after pretreatment with itraconazole 
(Itra), erythromycin (Ery), fluvoxamine (Flu), fluvoxamine plus erythromycin 
(FE) and ciprofloxacin (Cipr) presented as percentages of the corresponding 
values during the placebo phase. 
7.2 Effect of CYP1A2 inhibitors 
Fluvoxamine reduced the mean CL of intravenous lidocaine by 41% and prolonged the t½ 
of lidocaine by 35%. The mean AUC of lidocaine increased 1.7-fold. After oral 
administration of lidocaine, the mean AUC of lidocaine increased 3-fold  and the Cmax 2.2-
fold. 
Fluvoxamine decreased the Cmax of MEGX by 65% and the AUC of MEGX by 54%. 
The t½ was prolonged by 35%. The ratio of the AUC of MEGX to that of lidocaine was 
decreased by 73% by fluvoxamine. When lidocaine was taken orally, fluvoxamine 
decreased the Cmax and the AUC of MEGX by 47% and 26%, respectively. The ratio of 
the AUC of MEGX to that of lidocaine was decreased by 76%. 
After oral administration of lidocaine, the t½ of 3-OH-lidocaine was prolonged by 32% 
and the ratio of the AUC of 3-OH-lidocaine to that of lidocaine was decreased by 75% by 
fluvoxamine. 
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Compared with placebo, ciprofloxacin increased the mean Cmax and AUC of lidocaine 
by 12% and 26%, respectively. The mean plasma CL of lidocaine was reduced by 22% 
and its t½ prolonged by 7%. 
Ciprofloxacin decreased the Cmax and the AUC of MEGX by 40% and 21%, 
respectively. The t½ was prolonged by 34%, and the ratio of the AUC of MEGX to that of 
lidocaine was decreased by 40% by ciprofloxacin.  
Ciprofloxacin decreased the Cmax and the AUC of 3-OH-lidocaine by 22% and 14%, 
respectively. The ratio of the AUC of 3-OH-lidocaine to that of lidocaine was decreased 
by 35% by ciprofloxacin. 
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Figure 9 Mean elimination half-lives (t1/2) of either intravenous lidocaine (Liv) or oral 
lidocaine (Lpo) after pretreatment with itraconazole (Itra), erythromycin 
(Ery), fluvoxamine (Flu), fluvoxamine plus erythromycin (FE) and 
ciprofloxacin (Cipr) presented as percentages of the corresponding values 
during the placebo phase. 
7.3 Combined effect of CYP3A4 and CYP1A2 inhibitors 
During pretreatment with fluvoxamine combined with erythromycin, the mean CL of 
intravenous lidocaine was 53% smaller than during placebo and 21% smaller than during 
fluvoxamine alone. The t½ of lidocaine was significantly longer during the combination 
phase than during the placebo or fluvoxamine phase. The mean AUC of intravenous 
lidocaine increased 2.3-fold and the Cmax 1.4-fold. After oral administration of lidocaine, 
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the mean AUC of lidocaine increased 3.6-fold and the Cmax 2.5-fold. The t½ of oral 
lidocaine was significantly longer during the combination phase than during the placebo. 
The combination of fluvoxamine and erythromycin decreased the Cmax and the AUC of 
MEGX by 54% and 26%, respectively. However, this combination decreased the AUC of 
MEGX less than fluvoxamine alone. The t½ was prolonged by 59%, and the ratio of the 
AUC of MEGX to that of lidocaine was decreased by 68% by fluvoxamine and 
erythromycin. When lidocaine was taken orally, the combination decreased the Cmax of 
MEGX by 29% and the ratio of the AUC of MEGX to that of lidocaine by 65%. 
After oral administration of lidocaine, the combination of fluvoxamine and 
erythromycin prolonged the t½ of 3-OH-lidocaine by 36% and decreased the ratio of the 
AUC of 3-OH-lidocaine to that of lidocaine by 75%. 
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Figure 10 Mean peak plasma concentrations (Cmax) of either intravenous lidocaine (Liv) 
or oral lidocaine (Lpo) after pretreatment with itraconazole (Itra), 
erythromycin (Ery), fluvoxamine (Flu), fluvoxamine plus erythromycin (FE) 
and ciprofloxacin (Cipr) presented as percentages of the corresponding values 
during the placebo phase. 
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Figure 11 Mean ratio of the areas under the concentration-time curves (AUC) of MEGX to 
that of either intravenous lidocaine (Liv) or oral lidocaine (Lpo) after 
pretreatment with itraconazole (Itra), erythromycin (Ery), fluvoxamine (Flu), 
fluvoxamine plus erythromycin (FE) and ciprofloxacin (Cipr) presented as 
percentages of the corresponding values during the placebo phase. 
 
 
 
 
55
 
Table 4. Summary of the changes in the pharmacokinetics of a single dose of either 
1.5 mg/kg of intravenous (i.v.) lidocaine or 1 mg/kg of oral (p.o.) lidocaine 
after different pretreatments. 
 
Pretreatment Lidocaine MEGX 
 Route Cmax AUC t1/2 Cmax AUC t1/2
i.v. ↔ ↔ ↑ ↑ ↑↑ ↔ Erythromycin 500 mg x 3 for 4 days 
p.o. ↑ ↑↑ ↑ ↑ ↑ ↑ 
i.v. ↔ ↔ ↔ ↔ ↔ ↔ Itraconazole 200 mg x 1 for 4 days 
p.o. ↑↑ ↑↑ ↔ ↔ ↔ ↑ 
i.v. ↔ ↑↑ ↑ ↓↓ ↓↓ ↑ Fluvoxamine 100 mg x 1 for 5 days 
p.o. ↑↑↑ ↑↑↑ ↔ ↓ ↓ ↔ 
i.v. ↑ ↑↑↑ ↑↑ ↓↓ ↓ ↑↑ Fluvoxamine 100 mg x 1 for 5 days  
+ Erythromycin 500 mg x 3 for 6 days 
p.o. ↑↑↑ ↑↑↑ ↑↑ ↓ ↔ ↑↑ 
Ciprofloxacin 500 mg x 2 for 2.5 days i.v. ↑ ↑ ↑ ↓ ↓ ↑ 
Changes (increase or decrease) are indicated as follows: ↑/↓ a 10-50% change, ↑↑/↓↓ a 51-100% change, 
↑↑↑/↓↓↓ a > 100% change, ↔ no significant change 
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DISCUSSION 
1 Methodological considerations 
A randomized, double-blinded, placebo-controlled cross-over study design was used in all 
studies. In this design, the subjects serve as their own controls, minimizing the effect of 
interindividual variation and reducing the number of subjects needed. Based on previous 
studies, 8-10 subjects in each study was estimated to be sufficient to demonstrate a 25% 
difference in lidocaine AUC with a P < 0.05. Thus, the number of subjects exposed to the 
drugs was minimized. Balanced randomization and adequate wash-out periods (2-4 
weeks) were used to minimize the risk of possible period effects or carry-over effects. As 
physiological changes during the menstrual cycle seem to have only minor effects on the 
elimination of drugs (Kashuba and Nafziger 1998), we did not deem it necessary to have 
the wash-out period equal the average menstrual cycle of 4 weeks. 
The pretreatment period in the studies was between 2.5 and 6 days, and all CYP 
inhibitors were given at clinically relevant dosages. The steady-state concentrations of 
itraconazole and fluvoxamine were most probably not reached within this period. 
However, significant inhibition of CYP enzymes occurs even after a single dose of an 
inhibitor, and the pretreatments were similar to the ones previously involved in clinically 
significant drug-drug interactions (Neuvonen and Jalava 1996, Backman et al. 1998). In 
all studies, the dose of lidocaine was, for safety reasons, rather small relative to clinically 
used doses. The dose and rate of infusion of intravenous lidocaine were kept low to 
minimize the risks of toxicity. Thus, no lidocaine-related side-effects, except for mild 
cough irritation during lidocaine inhalation in Study III, were observed in any of the 
studies. As lidocaine has linear pharmacokinetics and the analysis methods applied were 
sensitive and specific, our results are likely to be valid also for the higher concentrations 
typically seen in clinical settings. 
To monitor compliance, the plasma concentrations of the pretreatment drugs were 
measured during the study days. These concentrations were at therapeutic levels, except 
for one subject in Study I, in whom no erythromycin was detected in plasma during the 
erythromycin phase of the study. In this subject, no erythromycin-associated changes in 
MEGX concentrations were observed. 
All subjects in the studies were young, healthy volunteers. Although the activities of 
CYP1A2 and CYP3A4 are quite constant during adulthood, the pharmacokinetics of 
lidocaine can change with increasing age and concomitant illnesses (Tucker 1986, Tanaka 
1998). Care must therefore be taken when extrapolating the results to elderly subjects. 
Variations in drug interaction may be greater in actual patient populations than in our 
healthy subjects. 
The studies were not balanced with respect to subjects’ gender. Many drugs 
metabolized by CYP3A4 show higher clearance in women than in men, and men have 
been described to have a higher CYP1A2 activity (Wolbold et al. 2003, Anderson 2005). 
In a recent review, Greenblatt and von Moltke (2008) postulated that gender has a small, 
most likely clinically negligible, influence on CYP3A phenotype for substrates not 
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transported by P-glycoprotein. Some of the female volunteers were using oral 
contraceptive steroids, which can significantly inhibit CYP1A2 and moderately inhibit 
CYP3A4 (Palovaara et al. 2000, Granfors et al. 2005). However, no balance with respect 
to gender or oral contraceptive use was considered necessary because the volunteers 
served as their own controls. Furthermore, due to the relatively small number of subjects 
in each study, we could not assess the effects of gender on the pharmacokinetics of 
lidocaine. 
Country of residence and ethnic origin can influence CYP1A2 and CYP3A4 activity 
(Yu et al. 2001, Ingelman-Sundberg et al. 2007, Gunes and Dahl 2008). All subjects in the 
studies were Finnish residents of Caucasian origin. Furthermore, they served as their own 
controls to minimize interindividual variability, and no CYP genotyping of the subjects 
was considered necessary. 
Stimulation of hepatic blood flow by food intake has been shown to influence 
lidocaine pharmacokinetics. A high-protein meal can increase the CL of intravenously 
administrated lidocaine by 20% and decrease its AUC by 20% (Elvin et al. 1981). Thus, 
the possible effect of food on the pharmacokinetics of lidocaine was controlled by using a 
standard fasting period before lidocaine intake and by serving standard meals after the 
intake. 
Venous blood samples were used in this work, as this was considered to be less 
harmful for the study volunteers. However, after intravenous administration, arterial 
plasma concentrations increase faster than venous concentrations and would have 
provided more exact data on the distribution phase of lidocaine. Nevertheless, since the 
study was more directed at examining the elimination phase, venous blood sampling was 
chosen. The first plasma sample was taken at 30 min following the end of the lidocaine 
administration, and venous samples were collected for up to 10 h. This timing largely 
ignored the distribution phase, but can be regarded as sufficient for characterization of the 
elimination phase. 
The plasma concentrations of lidocaine, MEGX and 3-OH-lidocaine (Studies V and 
VI) were measured with gas chromatography. The between-day CVs were low in all 
studies. The quantification limits and CVs for the methods of determining the plasma 
concentrations of erythromycin, itraconazole, fluvoxamine and ciprofloxacin were also 
satisfactory. 
2 Effect of inhibition of CYP3A4 on lidocaine pharmacokinetics 
The plasma concentrations of intravenously administered lidocaine were virtually 
unaffected by the concomitant administration of the CYP3A4 inhibitors erythromycin and 
itraconazole (causing an insignificant 9% and 14% reduction in CL). Although the mean 
elimination half-life of lidocaine was marginally prolonged after erythromycin, this 
obviously had no clinical consequences. However, when lidocaine was taken orally, both 
erythromycin and itraconazole increased lidocaine AUC and lidocaine peak concentrations 
by 40–70%. 
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Both erythromycin and itraconazole are potent inhibitors of CYP3A4 in vitro and in 
humans (Back and Tjia 1991, Gascon and Dayer 1991, Olkkola et al. 1993, Olkkola et al. 
1994). Because they do not appear to change liver blood flow, they are ideal model 
substances for the study of drug interactions at the level of inhibition of individual 
isoenzymes. Lidocaine is a drug with a medium to high extraction ratio, and therefore, its 
CL is significantly dependent on liver blood flow (Tucker and Mather 1979). The “well-
stirred model” of hepatic elimination (Rowland and Tozer 1995) enables estimation of the 
contribution of the changed intrinsic CL and liver blood flow on lidocaine CL (see 
Appendix 2). If the liver blood flow remains unchanged, a decrease of approximately 75% 
in the intrinsic CL of lidocaine is necessary to reduce lidocaine blood CL by 50%. The 
statistically insignificant 14% numerical decrease in lidocaine plasma CL by itraconazole 
is thus fully consistent with a possible 35-40% decrease in intrinsic CL. Unfortunately, we 
would have had to include 22 subjects to be able to demonstrate a statistically significant 
14% decrease in lidocaine CL. 
Recently, Yang et al. (2007) criticized the misuse of the “well-stirred model” and 
emphasized the importance of not mixing either plasma free fraction and hepatic blood 
flow or plasma and whole-blood clearance when using this model. In their opinion, one 
should take into account not only the free fraction in plasma but also the blood to plasma 
drug concentration ratio when using the model to estimate plasma and not blood clearance. 
In our estimation in Study I, this was done (see Appendix 2). 
Both erythromycin and itraconazole increase the bioavailability and concentrations of 
orally administered substrates of CYP3A4 such as buspirone (Kivistö et al. 1997), 
midazolam (Olkkola et al. 1993) and triazolam (Varhe et al. 1994). Considering that the 
oral bioavailability of lidocaine is only about 30% due to extensive first-pass metabolism 
(Tucker and Mather 1979), much greater effects on the pharmacokinetics of orally 
administered lidocaine would have been anticipated if lidocaine were metabolized 
primarily by CYP3A4. This suggests that in humans CYP3A4 has a lesser significance 
than previously assumed in the elimination of lidocaine or lidocaine has alternative routes 
of elimination. This finding is supported by earlier studies with propranolol, showing that 
it reduces lidocaine CL and increases the AUC of oral lidocaine by over 100% (Ochs et al. 
1980, Bax et al. 1985). This reduction in lidocaine metabolism is apparently mediated by 
both enzyme inhibition and reduction of liver blood flow (Tucker et al. 1984). Because 
propranolol does not affect the formation of MEGX, but inhibits the 3- hydroxylation of 
lidocaine mediated by CYP1A2 (Imaoka et al. 1990, Suzuki et al. 1993), it is logical to 
assume that also 3-hydroxylation is important in lidocaine metabolism in humans. 
Erythromycin increased the concentrations of MEGX markedly regardless of the route 
of lidocaine administration. The reason for this is unknown, but since MEGX is further 
metabolized, it is possible that erythromycin inhibits the metabolism of MEGX. Orlando 
et al. (2003) found a similar effect of erythromycin on MEGX concentrations and their 
conclusion was that erythromycin inhibits the de-ethylation of MEGX to GX, although 
GX concentrations were not significantly lower after erythromycin co-administration. 
MEGX has 33-83% of the anti-arrhythmic activity of lidocaine, and it can also cause 
convulsions (Burney et al. 1974). Unfortunately, our data do not justify any far-reaching 
conclusions about the clinical significance of the observed increase in MEGX 
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concentrations. From a theoretical point of view, during prolonged infusions, the 
accumulation of MEGX potentially could increase the toxicity of lidocaine. This increase 
in toxicity could be further strengthened by the fact that during prolonged infusion 
lidocaine clearance is also reduced, probably by the accumulation of MEGX (Thomson et 
al. 1987). Clearly, a pharmacodynamic study following lidocaine infusion to steady state 
would provide more information on this erythromycin-lidocaine interaction. 
In a later study, Swart et al. (2002) showed a similar insignificant effect of 
erythromycin on the pharmacokinetics of intravenous lidocaine (9% reduction in CL). The 
MEGX test was unaffected by erythromycin, but unfortunately the effect on the AUC of 
MEGX was not reported. In contrast, in the study by Orlando et al. (2003), erythromycin 
decreased lidocaine CL by 18%, and a greater increase in t½ (30% compared with 16% in 
Study I) was observed. 
The pharmacokinetics of inhaled lidocaine was unaffected by concomitant 
administration of itraconazole. This suggests that basically all lidocaine was absorbed 
from the airways and not from the gastrointestinal tract. For example, in local anaesthesia 
of the pharynx, a significant amount of lidocaine aerosol can be swallowed and be 
subjected to first-pass metabolism in the gastrointestinal tract. The pharmacokinetics of an 
inhaled drug is interesting. Most likely the fraction of the inhaled drug absorbed through 
the lung has the same disposition characteristics as an intravenous dose, and the 
swallowed fraction has a similar disposition as an orally administered dose (Taburet and 
Schmit 1994). Theoretically, inhaled lidocaine could be metabolized as it passes through 
the pulmonary epithelium during absorption. Studies in experimental animals have shown 
that the lung tissue of rabbits has enzymatic activity that is capable of metabolizing 
lidocaine (Le et al. 1996). In humans, substantial variation seems to exist in the pulmonary 
expression of CYP3A4 between individuals. In the human lung, CYP3A5 is the major 
CYP3A enzyme, and CYP3A4 is expressed in only about 20% of individuals (Anttila et 
al. 1997). CYP3A5 appears to be less susceptible to inhibition than CYP3A4 (Isoherranen 
et al. 2008). On the other hand, very little is known about the presence of CYP3A 
isoenzymes in the nasal cavity, pharynx, larynx and trachea (Raunio et al. 2005). Although 
CYP3A4 is poorly expressed in lungs, inhaled CYP3A4 substrates may be susceptible to 
interactions with the inhibitors of CYP3A4. In a study by Raaska et al. (2002), 
itraconazole considerably increased the plasma concentrations and delayed the elimination 
of inhaled CYP3A4 substrate budesonide. 
3 Effect of inhibition of CYP1A2 on lidocaine pharmacokinetics 
Fluvoxamine, a strong CYP1A2 inhibitor, markedly affected the elimination kinetics of 
intravenous lidocaine by reducing mean plasma CL by 41%. When lidocaine was given 
orally, fluvoxamine increased its Cmax and AUC 2.2- to 3-fold. Ciprofloxacin, a less potent 
CYP1A2 inhibitor, affected the elimination of intravenous lidocaine by moderately 
reducing its plasma CL and increasing its Cmax and AUC. 
Our studies and that of Orlando et al. (2004), nevertheless, demonstrate that the 
inhibition of CYP1A2 alone has a major effect on lidocaine pharmacokinetics. 
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Fluvoxamine is a potent inhibitor of CYP1A2 and also a moderate inhibitor of CYP3A4. 
Ciprofloxacin seems to be a less potent inhibitor of CYP1A2 than fluvoxamine (Bertz and 
Granneman 1997). Therefore, the observed 22% decrease in lidocaine CL caused by 
ciprofloxacin (41% reduction by fluvoxamine in Study IV) in Study VI is in good 
agreement with previous reports that ciprofloxacin is a moderately potent inhibitor of 
CYP1A2. However, in four of the nine subjects in Study VI, ciprofloxacin decreased the 
lidocaine CL by about 30–40%. As lidocaine has linear pharmacokinetics, this finding 
means that during a continuous epidural infusion of lidocaine its plasma concentrations 
could be increased up to 70% in these subjects. Clinically, ciprofloxacin can be 
administered in higher doses (up to 750 mg twice daily) than in our study. Thus, the 
plasma concentrations of ciprofloxacin can be higher and the (concentration-dependent) 
inhibition of CYP1A2 stronger than seen in our healthy volunteers. Furthermore, in 
patients, one could expect larger individual changes than in this small and rather 
homogeneous group. Consequently, the possibility of systemic toxicity cannot be 
excluded during the concomitant use of ciprofloxacin with lidocaine. 
Fluvoxamine considerably reduced the Cmax and AUC of MEGX and the ratio of AUC 
of MEGX to that of lidocaine and prolonged the t½ of MEGX. Ciprofloxacin also reduced 
the Cmax and AUC of the metabolites MEGX and 3-OH-lidocaine. The reduction of 
formation of both MEGX and 3-OH-lidocaine by ciprofloxacin demonstrates that 
CYP1A2 is important also in the formation of MEGX, a reaction earlier thought to be 
mainly mediated by CYP3A4. 
The mean reduction of the CL of lidocaine by ciprofloxacin or fluvoxamine was 
smaller than previously observed for another amide-type local anaesthetic ropivacaine 
(Jokinen et al. 2000, Jokinen et al. 2003). Knowing the dissimilar extraction ratios of these 
two drugs, this is not surprising. Ropivacaine has an extraction ratio of 0.4-0.5, which 
makes its plasma CL more dependent on the enzymatic capacity of the liver than in the 
case of lidocaine. Lidocaine is a drug with a high extraction ratio (Benowitz and Meister 
1978). Its CL is directly proportional to the liver blood flow, and even a major reduction 
in CYP1A2 activity does not challenge lidocaine CL as much as ropivacaine CL. 
4 Effect of combined inhibition of CYP1A2 and CYP3A4 on 
lidocaine pharmacokinetics 
The pharmacokinetics of lidocaine was affected more strongly when lidocaine was 
administered after combined pretreatment with fluvoxamine and the CYP3A4 inhibitor 
erythromycin. The large reduction of lidocaine CL was associated with prolongation of t½ 
and significantly increased AUC. The concomitant inhibition of CYP1A2 and CYP3A4 
affected the pharmacokinetics of intravenous lidocaine clearly more than the inhibition of 
either enzyme alone. When lidocaine was given orally, the use of erythromycin together 
with fluvoxamine had only an insignificant further effect (of 10–20%) on the Cmax and 
AUC of lidocaine, compared with the effect of fluvoxamine alone. 
In vitro, the results of enzyme kinetic, chemical inhibition, immunoinhibition and 
recombinant enzyme studies indicate that both CYP3A4 and CYP1A2 enzymes are 
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important in the metabolism of lidocaine, but their roles seem to be different at different 
lidocaine concentrations (Wang et al. 1999a, Wang et al. 2000). This phenomenon 
explains the apparent discrepancy between our results and those of Bargetzi et al. (1989), 
who previously suggested that CYP3A4 is the enzyme principally responsible for the 
metabolic clearance of lidocaine. At therapeutically relevant plasma lidocaine 
concentrations, CYP1A2 is the major enzyme catalysing the formation of both MEGX and 
3- OH-lidocaine (Wang et al. 2000). As stated earlier, Orlando et al. (2004) proposed that 
CYP1A2 and CYP3A4 are responsible for approximately two-thirds and one-third of 
lidocaine metabolism, respectively. 
The tissue distribution of these isoenzymes is different; CYP3A4 is extensively 
expressed in the gastrointestinal wall and liver, whereas CYP1A2 is mainly located in the 
liver (Shimada et al. 1994, Kivistö et al. 1996). Accordingly, the relative roles of CYP3A4 
and CYP1A2 in lidocaine metabolism can also depend on the route of its administration. 
Our work is in good agreement with that of Orlando et al (2004). In their study, in 
healthy volunteers, fluvoxamine decreased the clearance of lidocaine by 60% and 
prolonged the t½ by about 30%. The Cmax and AUC of MEGX were decreased by about 
60%. 
Although in Study I erythromycin alone caused a 9% non-significant decrease in 
lidocaine CL, in the Study IV the same dose of erythromycin decreased lidocaine CL by 
21% once CYP1A2 was inhibited. This is consistent with the effect of fluvoxamine and 
erythromycin on the pharmacokinetics of ropivacaine (Jokinen et al. 2000). In the 
condition of an uninhibited CYP1A2, this enzyme can compensate for the role of 
CYP3A4 in the metabolism of lidocaine and ropivacaine when the latter enzyme is 
inhibited by erythromycin or other CYP3A4 inhibitors. 
Continuous epidural infusion of lidocaine at doses of 0.44–0.98 mg/kg/h for 
postoperative analgesia produced lidocaine concentrations ranging from approximately 1 
to 4 µg/ml (Rygnestad et al. 1999). This is also the concentration range shown to be 
effective in the treatment of ventricular arrhythmias (Gianelly et al. 1967). Lidocaine 
results in subjective toxic symptoms already at plasma concentrations of 3-5 µg/ml and 
objective signs appear at 6-10 µg/ml (Benowitz and Meister 1978). Because fluvoxamine 
reduced the mean lidocaine CL by 41% and the combination of fluvoxamine with 
erythromycin by 53%, lidocaine concentrations during continuous epidural infusion can be 
calculated to increase on average by 70% and 110%, respectively. This means that both 
the interaction between lidocaine and fluvoxamine and the interaction between lidocaine 
and the combination of fluvoxamine with erythromycin can result in lidocaine-induced 
toxicity. Accordingly, Orlando et al. (2004) postulated that the lidocaine infusion rate 
should be greatly reduced (by 50%-80%) in patients taking fluvoxamine or other potent 
inhibitors of CYP1A2. 
When lidocaine was administrated orally in Study V, the Cmax of lidocaine after 
placebo ranged from approximately 50 to 220 ng/ml, and after fluvoxamine alone and 
together with erythromycin from 110 to 900 ng/ml. The highest individual rise in the Cmax 
of unchanged lidocaine was about 5-fold. In our studies, the dose of lidocaine was, for 
safety reasons, rather small relative to the clinically used doses. A usual oral dose prior to 
gastroscopy is 300 mg in adults, i.e. six times the dose administered to the smallest of our 
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volunteers in Study V (Sweetman 2009). Because lidocaine has linear pharmacokinetics, 
following an oral dose of 300 mg, peak plasma concentrations might be expected to attain 
level of 4-5 µg/ml in individuals using CYP1A2 and CYP3A4 inhibitors. During 
bronchoscopy, even greater doses of lidocaine (up to 8.2 mg/kg) are used, yielding peak 
lidocaine concentrations of up to 5.3 µg/ml (Milman et al. 1998, Langmack et al. 2000). In 
patients using CYP1A2 and CYP3A4 inhibitors or in those with compromised cardiac and 
liver function, even higher levels might be attained. 
Both fluvoxamine and concomitant erythromycin and fluvoxamine affected the 
pharmacokinetics of MEGX in Studies IV and V. However, erythromycin partially 
prevented the decrease in the AUC of MEGX caused by fluvoxamine. This opposite effect 
of erythromycin on the AUC of MEGX can be explained by the inhibition of other 
CYP3A4-mediated metabolic pathways of lidocaine by erythromycin or by inhibition of 
further metabolism of MEGX. This finding is in good agreement with Studies I and II, 
which demonstrated that after intravenous or oral administration of lidocaine, 
erythromycin increases the AUC of MEGX by 60-70%. Like lidocaine, MEGX has 
considerable anti-arrhythmic activity and can also cause toxic symptoms (Burney et al. 
1974). However, when lidocaine is administered together with fluvoxamine or with a 
combination of erythromycin and fluvoxamine, the plasma concentrations of MEGX are 
not higher than usual, and MEGX does not contribute to the toxicity of lidocaine. 
Similarly, erythromycin also partially reversed the modest, but statistically insignificant 
effect of fluvoxamine on the formation of 3-OH-lidocaine. 
The effect of the concomitant inhibition of CYP3A4 and CYP1A2 on the 
pharmacokinetics of lidocaine was less than that on the pharmacokinetics of ropivacaine. 
This is in line with the effect of inhibiting CYP1A2 alone, which is discussed above. 
5 General discussion 
The use of intravenous lidocaine as an anti-arrhythmic agent has diminished during the 
last years, but there are several new indications for its systemic use, including 
postoperative and neuropathic pain and some inflammatory conditions. Lidocaine has a 
narrow therapeutic window when it is used intravenously. High peak concentrations of 
lidocaine can also be seen following its administration by various routes (see Appendix I). 
Lidocaine is not for oral use, but is applied for topical anaesthesia in the oropharyngeal 
region, and in this indication it is also intentionally swallowed. There are several cases of 
lidocaine toxicity after accidental oral ingestion of lidocaine for topical anaesthesia (Hess 
and Walson 1988, Dawling et al. 1989, Gonzalez del Rey et al. 1994, Zuberi et al. 2000). 
In the present studies, a small dose of lidocaine was given intravenously, orally or 
inhaled without any intention to evaluate its pharmacodynamic effects or absorption 
following infiltration or conduction anaesthesia. These issues are, however, also important 
in clinical work. In addition to the dose, lidocaine absorption, and thus, the plasma 
concentrations, depend upon the rate of administration, dilution, vascularity of the area 
injected and co-administration of a vasoconstrictor (e.g. epinephrine). Duration of a neural 
blockade depends on absorption of the local anaesthetic from the site of administration. In 
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other words, absorption of local anaesthetics following a neural blockade is primarily and 
directly related to local blood flow and inversely related to local tissue binding (Tucker 
1986). 
From a theoretical point of view, it does not seem probable that erythromycin, 
itraconazole, fluvoxamine or ciprofloxacin would have a clinically significant effect on the 
absorption or the pharmacodynamics of lidocaine. Thus, it is not likely that these drugs 
would influence the duration or intensity of a single neural blockade produced by 
lidocaine, even if some of them affected the elimination of lidocaine. 
The systemic toxicity of lidocaine is related to its free plasma concentration, thus 
depending on both the absorption and the disposition of the drug (Tucker 1986). A 
reduction in Vss would lead to an increased Cmax, but the Vss of lidocaine was not altered 
by any of the drug interactions evaluated. 
Because lidocaine is metabolized by CYP1A2 and CYP3A4, we expected that drugs 
known to inhibit these enzymes would affect the pharmacokinetics of lidocaine. This 
proved to be true for CYP1A2 inhibitors, for combined use of CYP1A2 and CYP3A4 
inhibitors and also for CYP3A4 inhibitors when lidocaine was given orally. It is not 
uncommon that patients concomitantly use drugs that inhibit both CYP1A2 and CYP3A4, 
and then need lidocaine, for instance, for topical anaesthesia of the upper gastrointestinal 
tract. 
6 Clinical implications  
Itraconazole and erythromycin, given alone, had no significant effect on lidocaine CL. 
Inhibiting CYP3A4 alone therefore would not likely have a clinically significant effect on 
the pharmacokinetics of intravenous lidocaine.  
Itraconazole does not affect the plasma concentrations of inhaled lidocaine or its 
metabolite MEGX. Seemingly, no dosage adjustments are necessary if lidocaine is used to 
prepare the airway prior to endoscopic procedures or intubation in patients concomitant 
given CYP3A4 inhibitor. However, accidental ingestion of lidocaine may result in higher 
lidocaine concentrations than expected in these patients. 
The inhibition of CYP1A2 by fluvoxamine considerably reduces the elimination of 
lidocaine. A concomitant use of fluvoxamine and the CYP3A4 inhibitor erythromycin 
further increases lidocaine concentration by decreasing its CL. Thus, clinicians should be 
aware of the potentially increased toxicity of lidocaine when used together with the 
inhibitors of CYP1A2, particularly with the combination of drugs inhibiting both CYP1A2 
and CYP3A4 enzymes. Because the volume of distribution of lidocaine remains 
unchanged, the interaction is likely to have significant consequences only during 
continuous intravenous administration of lidocaine. 
When lidocaine is ingested, the inhibition of CYP1A2 by fluvoxamine considerably 
reduces the presystemic metabolism of lidocaine. The concomitant use of fluvoxamine and 
the CYP3A4 inhibitor erythromycin may further increase the exposure to oral lidocaine. 
Clinicians should be aware of the potentially increased toxicity of lidocaine applied to the 
upper respiratory or gastrointestinal tract when it is used together with the inhibitors of 
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CYP1A2, and, particularly, with the combination of drugs inhibiting both CYP1A2 and 
CYP3A4 enzymes. 
The inhibition of CYP1A2 by ciprofloxacin modestly reduces the elimination of 
lidocaine. Interindividual variation in the extent of this interaction exists, and, in some 
individuals, the interaction between lidocaine and ciprofloxacin may result in lidocaine 
toxicity. 
The influence of CYP interactions on toxicity of local anaesthetics is theoretical 
concerning single-dose nerve blocks. The changes in lidocaine elimination after a single 
intravenous dose are usually not of major clinical significance. On the other hand, during 
continuous infusions, the decreased CL of lidocaine by the CYP1A2 inhibitors may play a 
role in increasing the risk of systemic toxicity. In particular, fluvoxamine is a risky drug in 
this respect because, in addition to its major inhibition of CYP1A2, it also causes some 
inhibition of CYP3A4. In patients using fluvoxamine, clinicians should consider reducing 
the dose in repeated administrations of large amounts of lidocaine within a short time or in 
long-term continuous regional anaesthetic blocks or intravenous infusions. This can be 
even more important in patients with compromised cardiac and liver function. 
In conclusion, inhibitors of CYP1A2 and CYP3A4 are unlikely to affect the safety of a 
single injection of lidocaine. Clinicians should, however, be aware that in patients 
receiving a continuous lidocaine infusion or large doses of lidocaine in the oropharynx and 
concomitantly using potent inhibitors of both CYP1A2 and CYP3A4 high lidocaine 
concentrations can result.  
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CONCLUSIONS 
The following conclusions can be drawn on the basis of the results of Studies I-VI: 
 
Study I. Inhibition of CYP3A4 by erythromycin or itraconazole has only a minor effect 
on the pharmacokinetics of intravenous lidocaine. 
 
Study II. Erythromycin and itraconazole increase exposure to oral lidocaine by 40-70%. 
 
Study III. Itraconazole has no effect on the pharmacokinetics of inhaled lidocaine. 
 
Study IV. Inhibition of CYP1A2 by fluvoxamine reduces the elimination of intravenous 
lidocaine. The concomitant use of fluvoxamine and the CYP3A4 inhibitor erythromycin 
further increases lidocaine concentration by decreasing its CL. 
 
Study V. Fluvoxamine reduces the first-pass metabolism of ingested lidocaine. The 
concomitant use of fluvoxamine and erythromycin may further increase the exposure to 
oral lidocaine. 
 
Study VI. Inhibition of CYP1A2 by ciprofloxacin reduces the elimination of lidocaine. 
 
General. These findings underline the importance of studying drug interactions in humans 
to confirm or disprove predictions based on in vitro data. This work clarifies the role of 
CYP1A2, not CYP3A4 as previously thought, as the enzyme principally responsible for 
the metabolic clearance of lidocaine. Consequently, contrary to current beliefs, lidocaine 
and its primary metabolite MEGX cannot be considered as probes of CYP3A4 activity. 
Rather, they mainly reflect CYP1A2 activity. 
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APPENDIX 2. The “well-stirred” model 
The “well-stirred” model states that 
 
 
 
 
 
, where CLb,H is the hepatic clearance from blood, QH the hepatic blood flow, CLint the 
intrinsic clearance and fub the fraction unbound in blood (Rowland and Tozer 1995). Thus, 
if we assume that normal hepatic blood flow is 1.6 l/min, that the free unbound fraction of 
lidocaine in blood is 0.36 and that the blood to plasma concentration ratio is 0.8 (Tucker 
and Mather 1979) and then use the value of lidocaine CL calculated in Study I (mean 
value 0.9 l/min), we can determine how the change in CLint affects the CLb,H (Table 5). All 
other pharmacokinetic variables are assumed to remain unchanged by erythromycin or 
itraconazole. 
 
Table 5. Theoretical decrease in lidocaine blood clearance (CLb,H) after the 
decrease in intrinsic lidocaine clearance (CLint), as might be produced by 
the concomitant administration of erythromycin or itraconazole. 
% decrease in CLint % decrease in CLb,H 
5 1.5 
10 3.2 
25 9.0 
50 22.9 
75 47.1 
90 72.8 
95 84.9 
 
CLb,H =
QH · CLint · fub
QH + CLint · fub
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